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ABSTRACT 
Cervical cancer is to a large extent a preventable disease, through prophylactic human 
papillomavirus (HPV) vaccination and cervical cancer screening. Still, it is the second most 
common cancer among women in Argentina, with unchanged mortality rates for the last 30 
years, due to the absence of organized screening. In Sweden, with a well-organized screening 
program, cervical cancer burden is lower; however, the incidence is increasing again. This 
thesis has explored several aspects of cervical cancer prevention in different settings. The 
overall aim of this thesis is to improve cervical cancer prevention by contributing knowledge 
on i) vaccination acceptance, ii) barriers to screening and iii) the risk of recurrent/residual 
disease among women treated for precancerous lesions.  
 
Study I explored HPV vaccination acceptance among 174 young women aged 18-30 years 
from the Mendoza Province, Argentina, by using a structured questionnaire-based interview 
technique. HPV vaccination acceptance was at high 95%, and 75% stated that they were also 
willing to pay for vaccination. A statistically significant positive association was found 
between acceptance and belief in vaccine safety, and a statistically significant negative 
association between being a welfare recipient and acceptance if vaccination was not free. 
Educational campaigns ensuring the safety of vaccines, as well as clarifying other 
misconceptions are needed. 
 
Study II investigated maternal HPV vaccination acceptance among 180 mothers to girls aged 
9-15 years from the Mendoza province, Argentina, through use of a structured survey. HPV 
vaccination acceptance was 90% if it was free of charge, and 60% if it was not free. Being 
gainfully employed and having a higher disposable household income was significantly 
associated with acceptance of vaccination if it was not free, which suggests that cost could be 
an obstacle to catch-up vaccination and may lead to socioeconomic inequalities in uptake. 
Also, women with prior awareness of cervical cancer were more willing to pay for HPV 
vaccination, indicating the importance of improving awareness of HPV and its related 
diseases. 
 
Study III explored barriers and facilitators of screening compliance among 1510 women 
attending cervical cancer screening in Stockholm, Sweden through use of a structured survey. 
The mean total time and travel costs and direct non-medical cost per attendance were €55.6. 
Nearly half (44%) of the women did not attend screening within 1 year from their invitation, 
of which 51% cited difficulties in taking time off work. The most important correlates of 
higher screening compliance were not needing to take time off work, not having a companion 
and being of higher HPV knowledge. Increased flexibility by extended opening hours and 
improved general knowledge of HPV may facilitate screening compliance. 
 
Study IV investigated the long-term risk of recurrent or residual disease in relation to surgical 
margin status among 991 women who had undergone conization treatment of high-grade 
precancerous lesions at the Karolinska University Hospital in Sweden during 2000-2007. 
During a median of 10 years follow-up, 12% were diagnosed with residual or recurrent 
disease, based on data from the Swedish National Cervical Screening Registry. Women with 
involved margins had significantly worse outcomes compared to women with negative 
margins. The risk was almost 3-fold higher among women with involved endocervical 
margins, involved margins and uncertain as to whether these were endocervical or 
ectocervical, and especially when both margins were involved. These findings suggest that 
stratified margin status may contribute to the safety of the follow-up surveillance. 
 
In conclusion; this thesis provides improved knowledge on what may constitute barriers to 
HPV vaccination and cervical cancer screening, and delineates possible strategies on how to 
increase uptake of these prevention strategies. Ensuring the safety of HPV vaccines and 
educational campaigns on HPV and its related diseases appear important targets for achieving 
higher uptake. Also, our findings suggest that costs can be a barrier, both in the Argentinean 
setting, as well as to participation in cervical cancer screening in Sweden. It is thus important 
that the screening organization facilitates the participation of all women in Sweden, including 
all socioeconomic groups. Finally, the thesis shows that women treated for precancerous 
lesions with involved surgical margins are at high-risk of recurrent disease and differential 
risks could be shown with respect to which margin was affected. Future research 
should address the accuracy of combining margins status with established follow-
up surveillance. 
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1 INTRODUCTION  
Noble Prize winner Harald Zur Hausen made the first association between Human 
papillomavirus (HPV) and cervical cancer in 1976, which has dramatically changed the 
cervical cancer prevention field. Nowadays it is well established that HPV is necessary for 
cervical cancer development. This knowledge has led to several scientific breakthroughs such 
as the introduction of prophylactic HPV vaccines in 2006 and the more recent large-scale use 
of HPV tests to screen for cervical cancer as well as a test-of-cure during follow-up after 
treatment. The likewise important use of organized cervical cancer screening has dramatically 
reduced the burden of cervical cancer in many parts of the world. Despite these progresses 
within the field and that it to a large extent is a preventable disease, cervical cancer is the 
fourth most common cancer among women globally. There are still many obstacles to 
overcome, such as global inequalities in access to cervical cancer screening and HPV 
vaccination. Today cervical cancer prevention is often lacking in regions where it is needed 
the most. Also, in regions with well-established screening and vaccination programs, an 
important issue is to achieve high uptakes of screening and vaccination.  
 
Despite Argentina being an upper middle-income country, cervical cancer incidence is 
similar to figures seen in low-income countries. The country is lacking a well-functioning 
screening program and HPV vaccination may be the most beneficial way to reduce cervical 
cancer burden over time. Organized school-based HPV vaccination was introduced in 
Argentina in 2011, although data on vaccination acceptance in connection with this was 
scarce. In contrast, Sweden has a relatively low cervical cancer incidence and mortality due 
to the well-organized screening program. However, for not fully understood reasons, the 
incidence has now started to increase again. Largely, there are two major risk-groups of 
developing cervical cancer in Sweden; women who do not attend screening and those 
previously treated for precancerous cervical lesions.  
 
The final goal of this thesis is to contribute to cervical cancer prevention, both in countries 
with high and low burden of disease. There are different targets for improving cervical cancer 
prevention, and their relative importance differs between various settings of the world. 
Therefore, this thesis aims to i) explore HPV vaccination acceptance in Argentina, ii) identify 
barriers of cervical cancer screening in Sweden and iii) investigate the long-term risk of 
residual or recurrent disease among women previously treated for precancerous lesions in 
Sweden, and to assess this risk in relation to surgical margin status. Thereby, we hope to 
contribute with knowledge on strategies on how to increase vaccination and screening 
uptakes as well as on the risk-stratification of women treated for precancerous lesions. 
  
 2 
 
 
  3 
2 BACKGROUND 
2.1 CERVICAL CANCER 
2.1.1 The cervix 
The cervix is the lowest part of the uterus and is mostly composed of fibro-muscular tissue. 
It is subdivided into the endocervix and the ectocervix: the distal ectocervix (portio) 
protrudes into the vagina and is visible at pelvic examination using a speculum, while the 
proximal endocervix extends towards the uterus and is not visible. The cervical canal goes 
through the cervix and leads to the uterine cavity. The ectocervix is lined with a multi-
layered squamous epithelium and the endocervix, including the endocervical canal, is lined 
with a single layer of columnar epithelium. The transition area between these two types of 
epithelium is called the squamocolumnar junction (SCJ). Over time, a physiological process 
takes place, in which the fragile columnar epithelium is exposed to the acidic environment 
from the vagina, which results in replacement of the columnar epithelium with squamous 
epithelium, creating a new SCJ. This process is called metaplasia (1). The SCJ thus migrates 
thru life and goes from being fully visible at the surface of the portio in adolescence into the 
endocervical canal in post-menopausal women (2). The region between the old and new SCJ 
is called the transformation zone (TZ). For unknown reasons, this zone is especially 
susceptible to HPV infections and, consequently, most squamous cervical cancers arise from 
the TZ (Figure 1) (1). There are two main types of cervical cancer that originates from the 
two types of cervical epithelium: squamous cell carcinoma (SCC) and adenocarcinoma 
(ADC), where SCC by far is the most common (84%) (3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The anatomy of the cervix and the transformation zone. This image has been released as part of an 
open knowledge project by Cancer Research UK. If re-used, attribute to Cancer Research UK / Wikimedia 
Commons; 
https://commons.wikimedia.org/wiki/File:Diagram_showing_the_transformation_zone_on_the_cervix_CRUK
_375.svg. 
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2.1.2 Cervical cancer epidemiology 
Cervical cancer is the fourth most common cancer among women worldwide, after breast, 
colorectal and lung cancer, with an estimated 528,000 new cases and 266,000 deaths in 2012 
(4). In contrast to most other malignancies, almost half of the new cases are seen in women 
under the age of 50 (5). The worldwide distribution of cervical cancer varies greatly, with 
84% of all cases and 87% of deaths occurring in less developed regions. Cervical cancer 
remains the second most common cancer in less developed regions, while nowadays it is less 
common (11th) in more developed regions. The overall age-standardized cervical cancer 
incidence is 14 per 100,000, although ranging from 4.4 to 42.7 per 100,000. High-burden 
areas with an overall age-standardized incidence over 30 per 100,000 are Eastern, Southern 
and Middle Africa and Melanesia. In some of these regions—Eastern and Middle Africa—
cervical cancer is the predominant female cancer (4). Besides the above-mentioned regions, 
individual countries with an age-standardized incidence over 30 per 100,000 are also found in 
Latin America (5). In contrast, Australia/New Zealand and Western Asia represent the 
regions with the lowest incidence worldwide (Figure 2). The overall age-standardized 
cervical cancer mortality is 6.8 per 100,000 ranging from the lowest: 1.5 per 100,000 in 
Australia/New Zealand to the highest 27.6 per 100,000 in Eastern Africa (4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Age-standardized (world) incidence rates (per 100,000) of cervical cancer cases attributable to 
HPV in 2012. © 2017 International Agency for Research on Cancer (IARC/WHO); licensed by UICC, 
Reproduced with kind permission from de Martel et al (5).  
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2.1.3 Human papillomavirus and the etiology of cervical cancer  
It is now widely accepted that the sexually-transmitted HPV has a causative role in the 
development of cervical cancer. Retrospective studies have detected oncogenic high-risk 
HPV (HR-HPV) in almost 100% of all cervical cancers cases (6, 7). HPV is a large and 
heterogeneous family of viruses, with around 150 identified types infecting humans (8), of 
which around 30-40 infect the anogenital tract (9). Of these, 13 types are recognized as 
oncogenic to humans: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. Twelve of 
these HR-HPV types have been classified by the International Agency for Research on 
Cancer (IARC) as carcinogenic to the cervix and type 68 is classed as probably carcinogenic 
(10). HPV 16 is identified as the most potent HPV type in cervical carcinogenesis, followed 
by HPV 18 (10). HPV 6 and 11 cause condyloma (genital warts), but are not carcinogenetic, 
and are thus classified as low-risk HPV (LR-HPV) (10). A meta-analysis on the worldwide 
distribution of HPV types in 30,000 invasive cervical cancer (ICC) cases, showed that HPV 
16 was the most frequent HPV type in ICC in all regions of the world (57%, 95% Confidence 
Interval (CI), 54.3-58.9), followed by HPV 18 (16%, 95% CI, 14.6-17.4). Together they 
account for about 73% of all ICC. The next most common HPV types were HPV 58, 33, 45, 
31, 52, 35, 59, 39, 51 and 56 in descending order, although their relative order varied in 
different regions of the world. The distribution of HPV also differed between ADC and SCC. 
HPV 18 was most frequent in ADC (36.8%, 96% CI 34.9-39.7), while HPV 16 was most 
common in SCC (59.3, 95% CI 56.8-61.7) (11). 
 
2.1.3.1 HPV-related cancer outside the cervix 
It has been estimated that 2.2 million cancers worldwide, representing 15% of all cancers are 
caused by infectious agents. Around 640,000 of these cases were attributable to HPV, which 
makes HPV the second most common infectious agent in cancer worldwide, after 
Helicobacter pylori (which causes gastric cancer) (12). HPV has been estimated to cause 
4.5% of all cancer worldwide, 8.6% of all cancers in women and 0.8% of all cancers in men 
(5). IARC has classified HPV 16 as not only causing cervical cancer, but that sufficient 
evidence exists of its carcinogenicity in vaginal, vulvar, penile, anal, oral, oropharyngeal and 
tonsillar cancer. HPV 18 and 33 have also been associated with carcinogenesis outside the 
cervix (10). It has been estimated that 78% of all vaginal, 25% of all vulvar, 90% of all anal, 
50% of all penile and 30% of all oropharyngeal cancer is attributed to HPV (5).  
 
2.1.3.2 HPV transmission and prevalence  
HPV is the most common sexually transmitted infection (STI) worldwide, and most people 
will be infected with HPV at some point during their lifetime (10). Asymptomatic HPV 
infections are common in both men and women; however, HPV causes more disease in 
women due to the vulnerability of the cervix to HPV infection (13). The transmission rate 
seems to be higher for female-to-male transmission, with studies reporting a 19-81% 
cumulative incidence over a 6-month period, compared to a rate of 5-28% for male-to-female 
transmission.  It has also been reported that auto-inoculation from cervix to anus, or reversed, 
in the same individual is relatively common (14). A case-control study including over 5,000 
patients with head and neck cancer and 6,000 controls found that history of oral sex was 
significantly associated with cancer of the base of the tongue, oropharynx, and tonsil, 
suggesting a genital-oral transmission of HPV, as well (15). 
 
A large meta-analysis on over one million women has shown an overall prevalence of 12% in 
women with normal cytology. The highest estimates were found in Sub-Saharan Africa 
(24%), Eastern Europe (21%) and Latin America (16%). The most common HPV types 
globally are: HPV 16, 18, 52, 31, 58, 39, 51, and 56, where HPV 16 predominates in almost 
 6 
all regions, while the subsequent order of HPV types varies by region. HPV infection is most 
common among women below age 25 and declines with increasing age, although in many 
continents an unexplained second peak in HPV prevalence can be observed for middle-aged 
women (16). However, local very high prevalence of HPV has been reported. For example, a 
study on youth health clinic attendees in Stockholm found a notably high HR-HPV 
prevalence of 62% among this “risk-group”, of which 35% were HPV 16 positive and 61% 
were infected with more than one HR-HPV type (17). For men, reliable data on genital HPV 
prevalence is scarce, although it is estimated to be around 50%, although with a higher 
proportion of LR-HPV and lower rates of persistence (18) (14). Contrary to HPV infections 
in women, there is no clear age-distribution and HPV prevalence seems rather steady across 
age groups in men (18). 
 
2.1.3.3 HPV taxonomy and organization of HPV genome 
Papillomaviruses are small, double-stranded, non-enveloped ancient DNA viruses, which can 
be dated back several 100 million years. As previously mentioned, it is a large and diverse 
group and new papillomaviruses and HPVs are detected continuously. With few exceptions, 
HPVs mainly infect the skin, oral-, anal- and genital- squamous mucosal epithelia, as well as 
the endocervical columnar epithelia, but not epithelia in other locations (19). The HPVs are 
classified into Alpha-, Beta-, Gamma-, Mu- and Nu- papillomavirus based on their 
phylogenetic relationship, epithelial tropism, and diseases that they cause. The Alpha 
papillomaviruses can infect the mucosa and skin, while the others infect only the skin. Thus, 
the Alpha papilloma group includes LR-HPV which causes condyloma, as well as the 13 
previously mentioned HR-HPVs causing cervical cancer (8).  
 
The HPV genome consists of a control region and eight genes. The early genes E1, E2, E4, 
E5, E6, and E7 are important for the viral cell cycle, while the late genes L1 and L2 encode 
the capsid proteins (Figure 3) (8). E1 and E2 are involved in viral replication and are 
necessary for the initial amplification phase, while E5, E6, and E7 are important for the host 
cell environment, as the viral DNA replication uses the host cells replication system (8, 20). 
There are large differences between LR-HPV and HR-HPV regarding E6 and E7 protein 
functions, as well as promoter regulation (8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. HPV 16 structure and viral proteins. Reproduced with kind permission from de Sanjose et al. (13). 
 
2.1.3.4 The HPV life-cycle 
The squamous epithelium of the cervix is multi-layered and as the epithelia self-renews, new 
daughter cells migrate upwards after cell division. It is believed that the HPV enters the 
epithelium in the susceptible TZ through a micro-wound and accesses the basal layers of the 
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epithelium, that serve as a reservoir for the infection. Due to the natural cell division of the 
basal cells, new HPV-infected daughter cells are produced and migrate upward (8). When the 
epithelial cells differentiate, a large up-regulation of HPV gene expression takes place, 
including E6 and E7, as well as the late capsid genes (9). This results in complete virions 
being released at the surface with potential of transmission to others (Figure 4) (9, 13). It has 
been reported that HR-HPV, in contrast to LR-HPV, more often infects basal cells that still 
possess proliferative properties and also activates cell-proliferation to a greater extent in these 
cells (13).  
 
Figure 4. Life Cycle of High-Risk HPVs in Cervical Epithelium. Reproduced with kind permission from 
Doorbar et al. (8).  
 
2.1.3.5 Immune response to HPV and HPV clearance 
The viral life cycle is exclusively intraepithelial, without viremia, cell death, or inflammation, 
making it difficult for the immune system to detect the infection. Consequently, immune 
evasion is considered to be the hallmark of HPV infection (8, 9). Still, the majority (80-90%) 
of all HPV infections (including infections by HR-HPV) are transient and cleared by the 
innate immune system within one to two years (8). Recent studies have also pointed out the 
role of T-cells from the adaptive immune system in HPV clearance (21). Persistent HPV 
infection is necessary for the development of high-grade dysplasia or invasive cervical cancer 
and the risk increases with duration of persistence (22). It has been reported that long-term 
persistence of HR-HPV, i.e. for seven years or more, without development of cervical 
intraepithelial neoplasia grade 3 (CIN3) or worse is rare (14). Persistent HPV infection is 
more common in women above age 30 compared to younger women (22).  
 
It has been discussed whether or not a once cleared HPV infection can re-activate in the same 
individual. Figures on the frequency of re-detection of HPV after a documented clearing, 
range between 5-20%. It has been found that re-detection often is related to sexual activity 
and it has therefore been considered that re-detection is due to re-exposure to HPV. As HPV 
is cleared by the innate immune system, it does not result in memory cells, and re-infection is 
possible. However, in some women, antibodies can be detected, which suggests that they 
have probably had a persistent infection. Among these women, the relation between sexual 
activity and re-detection of HPV is not as clear, and the possibility of re-activation of a latent 
infection has not been ruled out completely (14).    
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2.1.3.6 HPV induced carcinogenesis 
The recognized mechanism of HPV carcinogenicity is by the production of oncoproteins E6 
and E7, which leads to a down-regulating of tumor suppressor genes p53 and retinoblastoma 
protein (pRb), that normally regulate uncontrolled or abnormal growth and protect against 
cancer. E7 binds to and degrades pRb, which controls cell cycle entry, while E6 indirectly 
mediates the degradation of p53. Further, E6 and E7 can inactivate interferon regulatory 
factor and thereby avoid detection by the immune system and avoid apoptosis (20). E6 has 
also been found to be capable of up-regulating telomerase activity (8).  The expression of E6 
and E7 is low in the early stages of infection, but increases over time through mutations and 
integration of viral DNA (20). It has been shown that the levels of E6 and E7 increase from 
CIN1 to CIN3. With further accumulation of genetic errors, these cells can progress to 
invasive cancer (8). It seems that E5 also contributes to carcinogenesis, although with a less 
significant role and mainly in the beginning of infection. E5 has been reported to stimulate 
cell proliferation and prevent apoptosis of DNA damaged cells (23).  
 
2.1.4 Co-factors and surrogate markers of HPV infection  
The single most important risk factor for cervical cancer is persistent HR-HPV infection; still 
only a few infected women will develop ICC. Other risk factors of cervical cancer, besides 
HPV, are now classified as either surrogate markers for risk of HPV infection or as co-factors 
among HR-HPV infected women (24). 
 
2.1.4.1 Sexual behavior and other STI 
Total number of sexual partners increases the risk of HPV exposure and hence cervical 
cancer. A lifetime number of 6 or more partners versus 1 partner is associated with a more 
than twofold risk of ICC (2.78, 95% CI: 2.22-3.47) and 11 or more partners with a threefold 
risk (3.15, 95% CI: 2.19-4.52). Early age at first intercourse has also been associated with an 
increased risk of ICC, also after adjusting for total number of sexual partners. Suggested 
explanations for this is that early sexual debut would serve as a marker of high-risk sexual 
behavior i.e. exposure to HPV, or that early intercourse could result in a longer lifetime 
exposure to HPV or that the cervix of young women is more susceptible to HPV infections 
(25). 
 
Co-infection with other STIs has been considered as a potential co-factor of cervical cancer, 
although results are conflicting and confounding effects of HPV have been suggested. A large 
study on half a million women found no association of herpes simplex type 2 and cervical 
cancer, when adjusted for HPV status and smoking (26). Neither did a large prospective 
study, in which biobank samples from women who had developed cervical cancer were 
analyzed regarding STIs (27). On the other hand, more evidence exists on a true association 
between Chlamydia trachomatis and cervical cancer. In the same prospective study, a 
statistically significant association between Chlamydia trachomatis and cervical cancer was 
found, also when restricting the analysis to HPV positive women (Odds Ratio (OR): 1.4, 95% 
CI: 1.1–2.0) (27). This association was confirmed in a recent meta-analysis, which showed a 
fourfold increased risk of cervical cancer among women with concomitant HPV and 
Chlamydia trachomatis infection (OR: 4.03, 95% CI: 3.15-5.16) (28). The cause of this is not 
known, although it has been reported that Chlamydia Trachomatis increases HPV persistence, 
possibly through chronic inflammation (29).  
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2.1.4.2 Hormonal contraceptives and high-parity 
Hormonal contraceptives and high-parity have also been discussed as co-factors of cervical 
cancer. After the finding of the important role of HPV in carcinogenesis, the significance of 
these associations has been questioned. Some studies restricted to women with HPV positive 
findings have shown a statistically significant increased risk of CIN3 and cervical cancer 
among women with over 5 years use of oral contraceptives (30, 31), while others have not 
(32). However, most studies support a significant association between oral contraceptives and 
cervical cancer, and that the risk increases with duration. Therefore, it has been classified as 
carcinogenic to the cervix by the IARC (33). A recent prospective study on more than 
300,000 women confirmed previous findings on oral contraceptive use, also after adjusting 
for HPV. Oral contraceptive was significantly associated with increased risk of cervical 
cancer and increased with duration of contraceptive use (Hazard Ratio (HR): 1.8 for oral 
contraceptive use ≥ 15 years compared to never use). In the same study, it was found that 
increasing number of full-term pregnancies was positively associated with CIN3; however, 
no significant association with cervical cancer was found (34). This association was, 
however, seen in a study on women with HPV positive findings, where the number of full-
term pregnancies increased the risk of cervical cancer compared to nulliparous women (OR 
2.3, 95% CI: 1.6-3.2 for 1 to 2 full-term pregnancies and OR 3.8, 95% CI: 2.7-5.5 for 7 or 
more full-term pregnancies). Neither the association between high-parity nor oral 
contraceptives in cervical carcinogenesis is fully understood.  However, it seems that oral 
contraceptives interact with hormone receptors and influence HPV expression of E6 and E7 
oncogenes, rather than making women more susceptible to HPV infection (33, 34).  
 
2.1.4.3 Smoking 
Smoking is identified as carcinogenic to the cervix by the IARC and considered an important 
co-factor for cervical cancer (35). In an analysis restricted to HPV positive women, a twofold 
risk of SCC was seen among smokers compared to never smokers (Relative Risk (RR): 1.95, 
95% CI 1.43-2.65) (36). In a more recent study on 300,000 women, a similar two-fold risk of 
either high-grade squamous intraepithelial lesions (HSIL) or ICC was seen among smokers 
compared to never smokers, after HPV adjustment. Smoking cessation reduced the risk (37). 
Smokers have been described as having more mutations in their cervical mucus and also a 
higher frequency of DNA adducts than non-smokers, which could implicate these 
mechanisms in cervical carcinogenesis (35). 
 
2.1.4.4 Immunosuppression 
Another important co-factor is immunosuppression. A meta-analysis on patients with Human 
immunodeficiency virus (HIV) and patients receiving immunosuppressive treatment due to 
transplantation found that both groups were more prone to develop HPV-related cancers as 
well as other infection-related cancers (38). Women with HIV-positive findings have been 
found to have a two to three-fold increased risk of acquiring HPV and lower rates of HPV 
clearance (RR 2.64, 95% CI: 2.04-3.42 and HR 0.72, 95% CI 0.62-0.84, respectively) 
compared to women who had HIV-negative findings. Also, the risk of cervical cancer is four-
fold higher in HIV-positive versus HIV-negative women (RR 4.1, 95% CI 2.3-6.6). The risk 
of acquiring HPV was higher in patients with low CD4 counts and lower in women on 
antiretroviral therapy (ART) (39). The importance of ART to reduce HPV related disease 
burden in HIV-positive women was confirmed in another meta-analysis, which showed lower 
risk of CIN2 or worse (OR 0.59, 95% CI, 0.40-0.87) as well as cervical cancer (HR 0.40, 
95% CI 0.18-0.87) among patients on ART (40).  
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2.1.4.5 Genetic predisposition 
Genetic predisposition has also been suggested as a co-factor for cervical cancer, since only a 
small percentage of women infected with HR-HPV develop CIN or cervical cancer (8). A 
registry-based study has shown an increased risk of cervical cancer among women with a 
first-degree or second-degree relative with cervical cancer, although this could be influenced 
by environmental as well as heritable factors (41). Most HPV infections are cleared by the 
immune system, such that host-factors related to this cell-mediated clearing could be 
important as to why some women develop HPV related disease. Absence of, or limited T-cell 
response to HPV antigens has been reported in women with cervical cancer (8). Human 
leukocyte antigen (HLA) is involved in antigen presentation and the association between 
variations of HLA and cervical cancer have been investigated in numerous studies. However, 
the evidence supporting this association is inconclusive (42).  
 
2.1.5 Precancerous lesions of the cervix  
2.1.5.1 Classification of precancerous lesions 
Cervical cancer develops over time and is preceded by precancerous lesions of various grades 
(43). There are different classification systems in use for grading the severity of these lesions. 
The system by Richart was introduced in 1966 and is based on histopathological findings 
(43). It grades precancerous lesions into cervical intraepithelial neoplasia, CIN, stages 1 to 3 
on the basis of the amount of abnormal cells and their appearance. CIN1 represents mild 
dysplasia, CIN2 moderate dysplasia and CIN3 severe dysplasia with atypical cells throughout 
the entire epithelium, equivalent to carcinoma in situ (CIS). Invasive cervical cancer, ICC, is 
defined by abnormal cells penetrating the epithelial basement membrane (Figure 5) (44).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic representation of the HPV infection in cervical mucosa and its different potential in 
squamous intraepithelial lesions. Reproduced with kind permission from de Sanjose et al. (13). 
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Due to the various terminology in use and inter-observer variability in grading lesions, a 
uniform classification system, the Bethesda system (TBS), was introduced in 1988, based on 
cytology (45). The nomenclature has been revised throughout the years, and current 
classifications include low-grade squamous intraepithelial lesions (LSIL) equivalent to CIN1 
and high-grade squamous intraepithelial lesions, HSIL, equivalent to CIN2/3. In addition, the 
Bethesda system has a nomenclature for atypical squamous cells of undetermined 
significance (ASC-US) and atypical squamous cells cannot exclude HSIL (ASC-H). Also, 
atypical glandular cells are sub-classed as atypical glandular cells not otherwise specified 
(AGC-NOS), atypical glandular cells, suspicious for AIS or cancer (AGC-neoplastic) and 
adenocarcinoma in situ (AIS) (Table 1) (46).   
 
New Swedish national cervical cancer guidelines from Jan 12, 2017 recommend a shift from 
the CIN-nomenclature to TBS for classification of cytological abnormalities (47), in line with 
European recommendations (48). The national recommendations include that also 
histopathological dysplasia should be classified as either LSIL or HSIL on the basis of 
international consensus (47, 49). For women aged 27 years or below, it is, however, still 
recommended to divide HSIL into CIN2 or CIN3 due to the high regression rate of CIN2 in 
this age-group (50). Young women with CIN2 could thus be kept under surveillance to avoid 
over-treatment (49). 
 
 
Table 1. Conversion table for different cytological classification systems. Reproduced with kind permission 
from Herbert et al. (51) 
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2.1.5.2 Natural history of precancerous lesions 
The natural history of precancerous lesions has been studied retrospectively during times 
when cervical lesions were managed conservatively. A Canadian study showed that most 
CIN1 and CIN2 would regress spontaneously, rather than progress. The cumulative 
percentage of progression from CIN1 to CIN3 or worse was 2% at 2 years, 6% at 5 years, and 
10% at 10 years. Corresponding figures for CIN2 to CIN3 or worse was 16% at 2 years, 25% 
at 5 years and 32% at 10 years (52). Reports on the risk of progression of CIN3 to cervical 
cancer have, for understandable reasons, been scarce. However, a long-term follow-up on an 
unethical clinical study from the 1960s, in which women were withheld treatment for CIN3, 
showed that the cumulative incidence of cervical or vaginal cancer was 31% within 30 years. 
In a subgroup of women with persistent CIN3 after 2 years, half (50%) of the women 
progressed to invasive disease by 30 years. In contrast, the corresponding cumulative 
incidence in women receiving adequate treatment was 0.7% (53). 
 
The regression rates have been reported to be higher in younger women. In a study on mainly 
younger women with a median age of 23 years, the regression rate of CIN2 was 
approximately 40% (54). The natural history of precancerous lesions is also influenced by 
HPV type. It has been found that women infected with HPV 16/18/45 are diagnosed with 
SCC at a younger age compared to women infected by other HPV types. This suggests a 
more rapid progression to invasive cancer through infection with any of these three HPV-
types (55). 
 
2.1.6 Invasive cervical cancer  
Cervical cancer is mainly spread by local invasion in the pelvis, but can also spread to 
regional lymph nodes or metastasize to lung, liver, bone and brain (56). Early stages of 
cervical cancer can be asymptomatic, while abnormal bleeding is a cardinal symptom (e.g. 
intermenstrual, post-coital and postmenopausal bleeding). Other symptoms include persistent 
vaginal discharge or in more advanced stages pain, e.g. due to compression of nerves, or 
symptoms from the rectum or bladder due to tumor spread to these organs (1, 57).  
 
After a histopathologically-confirmed diagnosis of cervical cancer, staging is performed, 
including tumor size, whether it has invaded adjacent organs or has spread to distant 
locations. There are different staging systems in use; staging according to the International 
Federation of Gynecology and Obstetrics (FIGO) system is a clinical evaluation, which has 
been useful for low-resource settings (58). FIGO-staging can also be performed by surgical 
staging, which has been found to be more accurate than clinical staging and is standard in 
many high-resource settings (59). Stage I is cancer that does not extend outside the cervix; 
subdivided into stage IA-IB2, with stage IA being microinvasive cancer and IB2 with lesions 
of 4 cm or larger. Stage II extends outside the cervix, up to the upper two thirds of the vagina, 
but does not involve the pelvic wall; stage III involves the pelvic wall or the lower one third 
of the vagina. Stage IV is disseminated disease, either to adjacent pelvic organs (urine bladder 
and/or rectum, stage IVA) or metastasized to distant organs (stage IVB) (60, 61). Another 
staging system is The American Joint Committee on Cancer (AJCC) Tumor, node, and 
metastasis (TNM) system, which additionally takes the lymph node status and pre-treatment 
radiologic examinations into account using computed tomography (CT), magnetic resonance 
imaging (MRI) and positron emission tomography (PET) scan (62). Survival rates are related 
directly to stage and the 5-year survival rates decline with increasing stage, from 76-98% in 
stage I, 66-73% in stage II; 40-42% for stage III to 9-22% for stage IV (63). However, lymph 
node invasion is another important prognostic factor of survival (64). Therefore, TNM 
staging has been suggested to be more accurate in assessment of prognosis (62). 
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Treatment is also based on staging, and early stages are mainly treated by surgery. Surgical 
procedures include fertility-preserving treatment with conization or trachelectomy for the 
earliest stages or simple hysterectomy or radical hysterectomy. Lymph node dissection is 
performed on all women, except those with stage 1A1 and no lymphovascular space 
invasion. Radiotherapy or chemotherapy can be used as adjuvant treatment depending on 
surgical findings and stage or to be used alone for later stages of disease (58).  
 
The global 5-year survival rate for women with cervical cancer has been estimated based on 
registry data on 660,000 women. The 5-year survival for women diagnosed 2010-2014 was 
found to be 60–69% in most countries. Japan, Korea, Taiwan, Denmark, Norway, 
Switzerland and Cuba were the only countries with an estimated 5-year survival rate of 70% 
or higher, while 13 countries were in the lower range between 50-59%, located in South and 
Central America, Asia and also some European countries. These global variations are 
presumably due to differences in stage at time of diagnosis and inequalities in treatment (65). 
 
2.2 PREVENTION BY CERVICAL CANCER SCREENING 
2.2.1 Cervical cancer screening 
The purpose of cervical cancer screening is to detect precancerous lesions and to treat them 
and thereby reduce cervical cancer incidence and mortality (66). The great impact of 
organized screening in reducing cervical cancer burden has, among others, been shown in 
several Swedish studies, in which a decline by approximately two-thirds has been observed 
(67-69). As mentioned above, the majority of all cervical cancer cases occur in less 
developed regions of the world (4), largely due to lack of or ineffective screening programs in 
these regions (70). Indeed, cervical cancer incidence in more developed regions was, before 
the introduction of organized screening, comparable to figures seen in less-developed regions 
today (71). The greatest impact of cervical cancer screening is seen on reducing SCC, while 
limited reduction has been shown for ADC (67-69). More developed countries have a higher 
proportion of ADC, and about one-fifth of all cervical cancer cases in these regions are ADC 
(3). In contrast to SCC, an increase of ADC has been seen in several European countries 
despite screening. A possible reason for this could be changes in sexual behavior with an 
increasing number of women being infected with HR-HPV, while at the same time the 
screening program is less effective for detecting ADC (72).  
 
2.2.1.1 Screening by conventional cytology 
The conventional cytology, i.e. the Pap smear from the 1940s, named after its developer Dr. 
George Papanicolaou, remains the screening standard method in many countries (73). 
Cervical cells are sampled from both the ectocervix and endocervix, then smeared onto a 
glass slide and fixated, often with 95% ethyl alcohol, and finally microscopically examined. 
European guidelines recommend the use of a spatula to collect material from the ectocervix 
in combination with an endocervical brush or using a cervical broom or an extended tip 
spatula alone. It is important that the sample includes material from the TZ, since, as 
described above, most dysplasia arises from this area (74). A systematic review has shown 
that the sensitivity and specificity for Pap smears to detect cytological abnormalities varies 
greatly, with figures ranging from 30-87% for sensitivity and 86-100% for specificity (75). 
Despite the often low sensitivity of Pap smear, its use has effectively reduced cervical cancer 
incidence, presumably due to the repeat testing within screening programs (73).  
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2.2.1.2 Liquid-based cytology  
Due to the low accuracy of conventional cytology and poor quality caused by obscuring 
factors (e.g. blood), the liquid-based cytology (LBC) technique was developed in the late 
1990s (76). Cervical cells are collected in the same way for LBC as for conventional 
cytology, but rinsed and preserved in liquid before being transferred to a microscope slide. 
Methods in use are ThinPrep (Cytyc, Boxborough, MA, USA) and SurePath system (TriPath 
Imaging Inc., Burlington, NC, USA) (74). It has been reported that LBC results in more 
uniform samples and less obscuring factors, and could thereby facilitate cytological 
assessments. Importantly, the method also facilitates supplementary testing, including reflex 
HPV testing. However, there is no evidence that cervical dysplasia is better detected by LBC 
than conventional cytology (73). A randomized controlled trial (RCT) on almost 90,000 
women did not show any statistically significant differences in detection rates between the 
two methods (76). Still, many of more developed countries have shifted to LBC (73). It is 
also the method in use for cytological diagnostics in Sweden (47).  
 
2.2.1.3 Primary HPV testing in cervical cancer screening  
The major discovery of the causal role of HPV infections in cervical cancer has spurred new 
approaches for cervical cancer screening using HPV testing. Evidence from four RCTs has 
found HPV-based screening to be more sensitive than conventional screening for detecting 
CIN3 (77-80). In 2014, Ronco and colleagues presented results from a follow-up study on 
these four RCTs, and were able to show a 60-70% greater protection also for ICC with HPV-
based screening compared to conventional screening. The study also found that the 
cumulative incidence of ICC was lower 5 years after a negative HPV test than 3 years after 
negative cytology. The authors recommended a shift to HPV-based screening for women 
over 30 years with a 5-year interval (81). The advantage of the HPV tests is thus the high 
longitudinal negative predictive value, i.e. very little risk of developing cervical cancer 
following a negative HPV test, which permits prolonged screening-intervals. This is very 
important also from a cost perspective (73). The follow-up study could not show any benefits 
in reducing ICC using HPV-based screening in women under the age of 30 (81). Also, in the 
previous study by Ronco et al. it was described that HPV-based screening leads to an over-
diagnosis of CIN2 in women aged 24-35, as CIN2 to a large extent would regress 
spontaneously in this age-group (77). This together led to recommendations that HPV-based 
screening should begin from the age of 30 (81).  
 
European guidelines on cervical cancer screening from 2015 now recommend primary HR-
HPV testing in the organized cervical cancer screening programs. It is also recommended that 
primary HPV screening should not begin under the age of 30 and that the screening interval 
should be at least 5 years for women with a negative primary HPV test, in agreement with 
results from the RCTs (82). These recommendations have also been implemented in Swedish 
guidelines (47).  
 
There are numerous different HPV tests on the market that detect viral DNA or RNA. HPV-
DNA is mainly detected by either hybridization with signal amplification, or by genomic 
amplification, typically using polymerase chain reaction (PCR) (73). Two HPV-DNA tests, 
Hybrid Capture2 (HC2), QIAGEN and GP5+/6+ PCR were used in most RCTs that 
compared HPV-based screening to cytology screening and detect all thirteen HR-HPV types 
(82). The reported pooled sensitivity of these two tests is 96.1 (95% CI, 94.2%-97.4%) and a 
specificity of 90.7% (95% CI, 90.4%–91.1%) (83). Due to the rapid development of different 
HPV assays, a guideline for HPV-DNA tests requirements has been developed. The 
recommendations include that the sensitivity should be not less than 90% of the sensitivity of 
Hybrid Capture2 and specificity no less than 98%, of the specificity of Hybrid Capture 2 and 
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have an intra-laboratory reproducibility of at least 87% (84). 
 
2.2.1.4 HPV self-sampling  
Another advantage of the HPV test is that it can be performed by self-sampling. In a meta-
analysis, it was found that the sensitivity to detect CIN2 or worse for HPV self-sampling was 
76% (95% CI, 69–82%) and the specificity to exclude CIN2 or worse was 86% (83–89%). 
This was significantly lower than HPV test performed by a clinician. Still, the test can have 
an important value, especially to be sent home to screening non-attendees, in order to 
increase adherence to screening (85). In a Swedish study, HPV self-sampling kits were 
delivered to 8,000 women who had not participated in screening for 6 years or more. The 
overall response rate was 39% and among those women who had an HR-HPV positive result, 
the majority (89%) went to follow-up examination. Almost one in four HPV positive women 
(23%) was found to have CIN2 or worse during follow-up (86). This emphasizes the 
importance of targeting this high-risk group.  
 
2.2.2 Follow-up colposcopy  
Women identified with HR-HPV positivity or cytological abnormalities through the national 
screening program are managed and followed-up according to standardized procedures (87). 
In Sweden, among women aged 23-29 years where cytology is the primary screening 
modality, a reflex HPV test is conducted on women with ASCUS or LSIL, while women 
with HSIL and ASC-H are referred to colposcopy without an HPV-reflex test. For women 
over the age of 30 years, a cytology reflex test is conducted on HR-HPV positive women – 
and women with cytological abnormalities are referred to colposcopy irrespective of the 
grade (47).  
 
Colposcopy is a procedure in which the cervix is examined with a colposcope, an 
instrument that illuminates and magnifies the cervix. It is used to detect visual 
abnormalities and to guide biopsy for histological assessment if there are abnormal 
findings. During the colposcopy, the lesion size, lesion borders, surface contours, the 
vascular pattern, acetowhite changes and iodine uptake are observed.  If dilute (3–5%) 
acetic acid is applied to the cervix, abnormal cells turn white. Acetowhite changes that last 
for one minute have an increased risk of being dysplasia. Similarly, applying Lugol iodine 
solution turns abnormal cells bright yellow (1, 88). Various findings on the accuracy of 
colposcopy to detect precancerous lesions have been reported. A meta-analysis found the 
sensitivity to detect all cervical abnormalities ranging between 87–99%, while the 
specificity was lower (23–87%) (89). A more recent meta-analysis from 2016 found 
sensitivity and specificity estimates to be more diverse, ranging between 29-100% and 12-
88%, respectively (90). Due to the low accuracy of colposcopy, different scoring systems 
for colposcopy assessments have been evaluated. The Swedescore has shown 95% 
specificity with a score of 8 points or more for CIN 2 or worse (90). The Swedescore are 
therefore used to assess colposcopy in Sweden (47). 
 
2.2.3 Treatment of precancerous lesions 
Due to the risk of progression of precancerous lesions to ICC, the guidelines from The 
American Society for Colposcopy and Cervical Pathology and the common practice is to treat 
women with histopathological CIN2 or worse (CIN2+). Younger women with CIN2 could, 
however, be kept under surveillance (87). Women under 25 years have a high incidence of 
CIN2 and high recurrence rate, while the cervical cancer incidence is low (91). CIN3, on the 
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other hand, should be treated regardless of age due to the higher risk of progression to ICC. 
CIN1 should be managed by observation, although persistent CIN1 should be treated, or 
closely followed-up if preceded by HSIL cytology. Treatment of CIN1 in younger women 
should be avoided (87). Swedish practices are in accordance with these guidelines (47). 
Treatment is mostly performed by excisional treatment (conization) where a cone-shaped 
portion of the cervix is removed or by non-excisional treatments. Common treatment 
modalities are loop excision of the transformation zone (i.e. LEEP (loop electrosurgical 
excisional procedure) in the US and LLETZ (large loop excision of the transformation zone) 
in the UK), laser conization, cryotherapy, cold knife conization and laser ablation. A 
Cochrane review on the different surgical treatment options found an overall success rate of 
around 90%. There was no evidence regarding the superiority of any treatment technique. 
Cryotherapy was mainly recommended for treatment of low-grade disease and was 
considered a good option for low resource settings due to low costs (92). Women who have 
been treated for high-grade dysplasia have an increased risk of recurrent CIN, cervical and 
vaginal cancer for at least 10-25 years after treatment, and it is therefore important that these 
women are followed adequately (93-96). The risk of recurrence remains increased for at least 
10-25 years post treatment (94-96). A recent meta-analysis found an overall 
recurrence/residual rate of 6.6% among women treated for CIN (97).  Women with involved 
margins in the cone biopsy have been reported to have a higher risk of recurrent disease (97, 
98). This is also the case for women with HPV persistence during follow-up. Co-testing with 
HPV test and cytology as a test-of-cure is now supported by international guidelines and 
existing evidence (87, 99).  
 
2.2.3.1 Side effects of treatment 
There are perioperative and postoperative complications related to treatment of precancerous 
lesions and overtreatment should be avoided. Reported short-term complications include 
bleeding, infections or damage to nearby organs. A meta-analysis from 2016 compared 
complications related to LEEP, cryotherapy and cold knife conization, and found adverse 
events to occur in less than 1% of women who were treated, although bleeding was more 
common with cold knife conization (2.4%). It was, however, noted that the studies often were 
of low quality and that more studies assessing the frequency of complications were needed 
(100). Several meta-analyses have investigated the risk of adverse pregnancy outcomes after 
treatment of CIN. In a 2017 meta-analysis by Kyrgiou et al. (101), treatment was associated 
with an almost twofold risk of premature birth (<37 weeks) (RR 1.75, 95% CI, 1.57 -1.96). 
The risk was highest after cold knife conization, (RR 2.70, 95% CI, 2.14-3.40) followed by 
laser conization (RR 2.11, 95% CI, 1.26-3.54) and somewhat lower for LLETZ (RR 1.58, 
95%, CI 1.37-1.81). Women with several treatments had an almost four-fold increased risk 
compared to women without previous treatment (RR 3.78, 95% CI, 2.65-5.39). It was also 
found that the risk increased with greater depth of the surgical specimen from a RR of 1.54 
(95% CI 1.09-2.18) with a depth of 10-12 mm or less, to a RR of 4.91 (95% CI 2.06-11.68) 
with a depth of 20 mm or more. It should, however, be noted that women with CIN had a 
higher baseline risk of premature birth compared to the general population which indicates 
that the results could also be influenced by other confounding factors (101).  
 
2.2.4 Barriers and health economic aspects of screening   
2.2.4.1 Health economic aspects 
Health economics represents an interdisciplinary method to assess the value of health policy 
decisions, taken in complex settings, to improve healthcare. Since resources are scarce, health 
economics is concerned with issues relating to efficient allocation of given resources to 
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maximize health outcomes (102). According to the guidelines by the World Health 
Organization (WHO) and the Swedish National Board of Health and Welfare 
[Socialstyrelsen], health policymakers need to ascertain both the clinical effectiveness and 
cost-effectiveness of any population-based screening program (103, 104). Given that 
compliance with cervical cancer screening is crucial to both these factors, eliminating 
potential barriers is especially important.  
 
Women who do not to participate in cervical cancer screening have an increased risk of 
cervical cancer (66). Cervical cancer prevention can thus be optimized further by increased 
screening coverage also in countries with already well-established cervical cancer screening 
programs (105). The screening uptake in the member states of the European Union has been 
found to vary between 10-79% and Sweden represented the country with the highest uptake 
(106). However, the screening uptake has been reported to have declined in younger women 
in many developed countries (107). A study from Sweden found an association between 
young age and lower participation rate. Other factors associated with lower participation were 
being single and not being in the labor force (108). Another Swedish study found immigrant 
women to have a lower participation rate than Swedish-born (49% to 62%) (109). This was, 
however, not shown in a large population-based case-control study on 600,000 Swedish 
women, when adjusting for socioeconomic factors. The study did show a strong association 
between socioeconomic status and screening participation. Important factors associated with 
lower screening participation were low disposable family income (OR 2.06; 95% CI, 2.01-
2.11), low education (OR 1.77, CI 1.73-1.81) and not cohabiting (OR 1.47, CI 1.45-1.50) 
(110). A meta-analysis on qualitative research addressed how women’s experiences and 
perceptions influenced screening uptake. Two major themes were identified: questioning the 
relevance and the value of participation and screening posing a threat or previous negative 
experiences (111). Strategies discussed to increase adherence to screening could be through 
use of invitations and reminders. Another promising option to increase screening adherence 
could be use of HPV self-sampling among non-attenders, as described above (105).  
 
A screening program in general has to be cost-effective on a large scale (103). However, also 
cost incurred by the patient is important to consider. A study that investigated participation in 
mammography screening among low-income women found a higher participation rate among 
women who randomly were given a voucher for a free mammogram compared to those who 
had to pay the fee. The main reason for non-participation among women without a voucher 
was cost, while it was transportation for those with a voucher (112).  A meta-analysis on 
strategies to improve cancer screening attendance concluded that the most effective 
interventions were organizational change, followed by patient financial incentives and patient 
reminders (113). However, there is very little research that relates to indirect costs (e.g. time 
spent on the screening visit) or direct-non-medical costs of screening (e.g. cost related to 
transportation, child care or parking).  
 
2.2.4.2 Barriers in developed countries 
As described above, there are large differences in cervical cancer burden between less 
developed and more developed countries, primarily due to the existence of screening 
programs. The main barriers to screening implementation in less developed countries are 
poverty, as well as related problems of lack of healthcare infrastructures and trained 
personnel needed for the complex screening process (114). Some less developed countries 
have opportunistic screening, which means that screening is performed if women seek 
gynecologic care for other reasons. According to the WHO, opportunistic screening programs 
mainly cover young women at low risk of cervical cancer, while organized screening 
programs target the risk population more cost-effectively (1). As previously discussed, HPV 
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tests have a higher longitudinal negative predictive value than conventional screening and 
screening intervals can be prolonged (73). A 2016 study that estimated the costs for different 
screening scenarios in less developed regions concluded that a shift to HPV based screening 
may be cost-beneficial (115).  
 
2.3 PREVENTION BY HPV VACCINATION 
2.3.1 HPV Vaccines 
2.3.1.1 Development of vaccines 
The development of HPV vaccines has greatly improved the possibility to prevent cervical 
cancer. Prophylactic HPV vaccines have been available since 2006 and among the first 
countries to introduce organized HPV vaccination were Australia, Austria, Belgium, Canada, 
France, Germany, Italy and the US (116). By 2017, HPV vaccine had been implemented to 
national vaccination programs in at least 71 countries (117), and an estimated 118 million 
women had been vaccinated in 2014 (118). The two vaccines used throughout the world are 
the bivalent (Cervarix
®
, GlaxoSmithKline) and the quadrivalent (Gardasil
®
, Merck and Co). 
Both vaccines protect against HPV16 and 18 (119), which, as mentioned previously, account 
for around 70% of all ICC (11). The quadrivalent vaccine also protects against HPV types 6 
and 11, responsible for causing > 90% of condyloma (120). In 2014, the US Food and Drug 
Administration (FDA) approved a nonavalent vaccine (Gardasil 9
®
, Merck and Co), 
targeting a total of 9 HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58) (119), which together 
cause 90% of all cervical cancers (5).  
 
2.3.1.2 Immunogenicity and duration 
All three vaccines contain virus-like particles (VLPs) against the included HPV types. The 
VLPs are empty, non-infections protein shells, derived from the L1 capsid, that mimic the 
authentic virus. The mechanism of protection is through humoral immunity by antibodies, 
mainly IgG (119). The antibody levels induced by vaccination have been reported to be 10-
100 times higher than after a natural HPV infection (121). The exact duration of protection 
conferred by HPV vaccination, and the need for eventual booster doses, is still unclear. 
Studies have so far shown sustained high antibody levels during 10-years of follow-up, 
suggesting a maintained protection for decades (122, 123). Also, the 9-valent HPV vaccine 
has shown sustained protection after 5 years (124, 125), as has the bivalent vaccine, if 
administered by two-doses, after a median of 7 years (126). 
 
2.3.1.3 Efficacy of HPV vaccines 
The main HPV vaccine trials are FUTURE I (127) and FUTURE II (128) for the quadrivalent 
vaccine, while PATRICIA (129) and the Costa Rica vaccine trial (130) are the main trials for 
the bivalent vaccine. All trials have been randomized, double-blind and placebo-controlled. It 
has been shown that almost 100% of girls and women seroconvert to the included HPV types 
following immunization with either vaccine (131). A 2011 meta-analysis on RCTs (including 
FUTURE I and II and PATRICIA) in which more than 44,000 women were included, found 
both vaccines to be highly efficacious, with 94-95% efficacy against persistent HPV 16/18 
infections and 90-96% efficacy against HPV 16/18 related CIN2+ in per-protocol populations 
of women without prior infection by the included HPV types. The vaccines have also been 
shown to have a cross-protective efficacy for some phylogenetically related HPV types not 
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included in the vaccines. The overall cross-protection for HPV 31/33/45/52/58 related 
persistence or CIN2+ was 28% and 42%, respectively, which suggests even higher protection 
rates against cervical cancer (132). The cross-protective efficacy of the two vaccines was 
compared in another meta-analysis, and the quadrivalent vaccine was found to be efficacious 
against only HPV 31-related outcomes, while the bivalent vaccine was efficacious against 
outcomes related to HPV 31, 33, and 45 (133). In 2016, a 10 year follow-up study was 
published on the impact of the quadrivalent vaccine. It was reported that up to 90% of 
persistent HPV 6/11/16/18 infection, up to 90% of condyloma, up to 45% of LSILs and up to 
85% of HSILs had been reduced among those who were vaccinated (134).  
 
There are several ongoing RCTs evaluating the nonavalent vaccine (135). The first to 
evaluate vaccine efficacy was a double-blind RCT, in which 14,000 women were 
administered either the quadrivalent or the nonavalent vaccine (136). The final efficacy, 
immunogenicity and safety evaluation from the study were published in 2017, and showed a 
97% efficacy against HPV 31/33/45/52/58 related high-grade cervical, vulval, and vaginal 
disease. It was also shown that the immune response and antibody levels to HPV 6/11/16/18 
were non-inferior compared to those who received the quadrivalent vaccine (125). Studies 
have also shown that the nonavalent vaccine is safe and efficacious, also for women 
previously vaccinated with the quadrivalent vaccine (137).   
 
2.3.1.4 Vaccination of different age-groups 
The recognized strategy for HPV vaccination is to target adolescent girls prior to the initiation 
of sexual activity, as HPV is transmitted through sexual contact. The American Academy of 
Pediatrics therefore recommends vaccination for girls aged 11–12 and catch-up vaccination 
for females aged 13–26 years (138). It has also been shown that girls reach higher antibody 
titers compared to adult women (139, 140), and that the titers remain higher over time (123). 
HPV vaccines were first administered by three-doses (including the main trials) but recent 
trials have shown that two doses of the vaccines were non-inferior in girls/young women 
(141, 142). In 2014, the WHO therefore revised their recommendations to a two-dose 
regimen for HPV vaccination for girls aged 15 years or younger (119). This change will 
result in both cost- and logistic benefits and is projected to be especially important for low-
income countries (142). Also, the nonavalent HPV vaccine has been shown to generate non-
inferior immunogenicity when administered by 2-doses (143). The 2-dose regimen is now 
approved by the FDA also for the nonavalent vaccine (144). 
 
The immunogenicity of HPV vaccines in older women has been studied on women up to age 
45 years for the quadrivalent vaccine and on women up to age 55 years for the bivalent 
vaccine (145, 146). Although older women produced lower levels of antibodies compared to 
younger women (145, 146), both vaccines showed high levels of protection against HPV 
persistence and CIN1. However, no risk reduction could be shown for CIN2+, which could 
be due to a low incidence in this age group (145, 147) 
 
2.3.1.5 Vaccination safety 
All three vaccines have shown excellent safety profiles. The meta-analysis on the vaccine 
trials concluded that there were no statistically significant differences regarding serious 
adverse events between HPV vaccines and placebo (RR 1.00, 95% CI: 0.91-1.09) nor 
vaccine-related serious adverse events (RR, 1.82; 95% CI: 0.79-4.20). Mild adverse events 
such as pain at injection site, headache and fatigue were common (132). The nonavalent 
vaccine has also found to be safe, although with a higher occurrence of adverse events related 
to the injection site (most commonly pain, swelling, erythema, and pruritus) compared to the 
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quadrivalent vaccine (91% and 85%, respectively). This was expected, due to a higher 
amount of VLPs and adjuvant dose used for the nonavalent vaccine (136).   
 
As mentioned above, around 118 million women had been HPV vaccinated by the end of 
2014 (118), contributing to the post-licensure surveillance regarding vaccination safety. A 
large population-based cohort study from Sweden and Denmark, including around 700,000 
doses of the quadrivalent vaccine; found no association between HPV vaccine and 
autoimmune, neurological or venous thromboembolic adverse events (148). A 2017 updated 
review on vaccination safety concluded that HPV vaccines are safe based on evidence from 
over 100 publications (117). Complex Regional Pain Syndrome (CRPS) and Postural 
Orthostatic Tachycardia Syndrome (POTS) have controversially been associated with HPV 
vaccination, although evidence from systematic reviews, expert analyses by WHO Global 
Advisory Committee on Vaccine Safety (GACVS) and the European Medicines Agency 
(EMA) has shown no causal association (117).  
 
2.3.1.6 Male vaccination 
The quadrivalent vaccine has been licensed for males for some time in many countries (119) 
and the bivalent and the nonavalent is now also approved for use in boys and men (119, 149). 
Recent data has shown that anal and HPV-related oropharyngeal cancer is increasing in 
developed countries in both sexes (119, 150). It is projected that HPV-related oropharyngeal 
cancer would exceed the number of cervical cancers in the US by the year 2020 (151). Also, 
men who have sex with men (MSM) have been shown to be a high-risk group for HPV 
infection and HPV-related cancers, and will not be protected by herd immunity by HPV 
vaccination of females (152). Therefore, there is an ongoing debate whether to expand HPV 
vaccination to males, and Australia was the first country to include boys in their vaccination 
program in 2013. Since then, the US, Austria, Czech Republic, Lichtenstein, Switzerland and 
Norway have followed (149, 153). 
 
2.3.2 Barriers to HPV vaccination implementation 
The introduction of HPV vaccination is key for reducing the global cervical cancer burden, 
and will have the greatest impact in regions with the highest burden of disease (154). 
However, it has been reported that only 1% of the 118 million women who had been targeted 
through national vaccination programs by 2014, were from low-income or lower-middle-
income countries. The populations at greatest risk thus remain, to a large extent, unprotected 
(118). Among the challenges for universal HPV vaccination are high vaccination costs, the 
maintenance of the cold chain (production, transportation and storing vaccines adequately 
refrigerated), logistics of implementation of HPV vaccines and vaccination uptake and 
adherence to the two or three-dose regimen (21, 155). Many low- and middle- income 
countries with insufficient cervical cancer screening still have well-functioning child 
vaccination programs (156). The long-term duration of protection of HPV vaccines seen so 
far, suggests that a feasible option for HPV vaccination implementation could be through 
such existing programs (21). 
 
2.3.2.1 Uptake and vaccination acceptance  
The most important factor for the impact of vaccination is to attain adequate coverage of the 
population (156). A study on the impact of HPV 16/18 vaccination on a cohort of 12 year old 
girls in the UK showed that a theoretical 100% vaccination uptake would reduce cervical 
cancer incidence and mortality by 76%, but for only 61% if vaccination covered 80% of the 
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cohort (157). Economic analyses have regarded vaccination coverage of 70% as the threshold 
for ideal cost-effectiveness (118). Still, many countries have not reached such coverage (21). 
A recent national immunization survey used by the Centers for Disease Control and 
Prevention (CDC) in the US showed that only 42% of girl in ages 13 to 17 years had received 
all doses of the vaccine. A somewhat higher share (63%) had received at least one dose. Still, 
this was considerably lower in comparison to other childhood vaccines, with corresponding 
figures for Diphtheria, Pertussis and Tetanus (DPT) and meningococcal vaccine of 86% and 
81%, respectively (158). The lower uptake of HPV vaccine in comparison to other vaccines 
has also been seen in Sweden. Registry data with complete information on vaccinations 
within the national immunization program from 2016, showed a 2-dose uptake of HPV 
vaccination of birth cohorts 2000-2004 of 73-77%. At the same time, uptake of DPT and 
Measles, Mumps, and Rubella (MMR) was above 95% (159). Following the controversial 
association of POTS and CRPS described above, and other disbelieves in vaccination safety, 
vaccination uptake in Denmark, Japan and Ireland declined (117).  
 
Parental vaccination acceptance is important to achieve high vaccination uptake (155). A 
systematic review on parental HPV vaccination acceptance found a wide range of acceptance, 
between 55 to 100% (160). A similar range was also seen in another meta-analysis on adult 
women regarding vaccination for self (50-94%) (161). Potential predictors of HPV vaccine 
acceptance were HPV knowledge, perceived severity of HPV-related disease, perceived 
effectiveness of vaccines, history of HPV-related disease, self-perception of risk, age, marital 
status, socioeconomic status, costs and lack of misinformation (160, 161). Two Swedish 
population-based studies from 2010 investigated parental acceptance and acceptance among 
young adults, with more than 10,000 respondents each. Acceptance was similar among 
parents and adult women when vaccination was free (76% and 75%, respectively), while 
considerably lower for adult women (41%) compared to parents (63%) if vaccination came 
with a cost. The strongest correlates of acceptance were belief in vaccine safety and in its 
efficacy. Other positive predictors were prior awareness of HPV, young age, low education, 
or having someone in the family receiving social welfare (162, 163). Also, the 
recommendation on vaccination from health care providers has been found critical for 
vaccination acceptance (164). An RCT on 40,000 participants showed that health 
interventions could be used to increase HPV vaccination initiation (165). The majority of all 
studies on HPV vaccination acceptance have been conducted on highly-educated populations, 
while few investigations have targeted those with low-education, low-income and/or living in 
rural settings. It has been pointed out that there is a need for studies from low resource 
settings (166).  
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2.4 CERVICAL CANCER IN DIFFERENT SETTINGS 
2.4.1 Argentina 
2.4.1.1 Cervical cancer incidence and 
mortality in Argentina 
Argentina is a high middle-income country, in 
which cervical cancer remains a major public 
health problem (167). In 2008 there were an 
estimated 4,000 new cases and 1,800 cervical 
cancer related deaths, which makes cervical 
cancer the third most common female cancer in 
the country and the second most common 
cancer among females aged 15-44 years (168). 
Despite Argentina being a relatively wealthy 
country, the age-standardized cervical cancer 
incidence was 20.8 per 100,000 in 2012 (5), 
which is actually higher than the global 
average of 14.0 per 100,000 and comparable to 
figures seen in low-income countries (4). 
Figures on the age-standardized mortality rate 
from 2008 were, however, slightly below the 
global average (7.4 and 7.8 per 100,000, 
respectively) (168). Still, according to national 
statistics from the Argentinean government, the 
mortality has remained almost unchanged, and 
even increased slightly between 1980 and 2009 
(7.1 to 7.5 per 100,000 women) (169). This 
does not necessarily imply a true increase in 
mortality, but may rather be the result of 
improved diagnostic methods and statistics. On 
the other hand, mortality does not appear to have 
decreased, even though cytological screening has 
been practiced for over 50 years (170). However, on a promising note, the 5-year cervical 
cancer survival rate has been reported to have increased in Argentina from 46% to 51% over 
a 10 year period between 1995–99 and 2005–09 (171).  
 
2.4.1.2 Organization of cervical cancer screening in Argentina  
Cervical cancer screening is mainly opportunistic in Argentina, performed by opportunistic 
cytology on women seeking health care for other reasons. Before 1998, Argentina did not 
have a national prevention program for cervical cancer (170). After the implementation of 
The National Program on Cervical Cancer Prevention, the previous screening 
recommendations on annual smears from sexual debut to age 64 were revised to the current 
recommendations on a three-year interval, after two negative annual Pap smears, for women 
aged 35 to 64 (172). However, the Argentinean health care system is highly decentralized and 
managed at the provincial level and screening policies vary across the 24 provinces (Figure 
6). A study from 2010 investigated the provinces’ adherence to the national guidelines. It was 
found that target age varied between 10-70 years and that screening remained annual in some 
provinces. Two provinces did not have an official framework for cervical cancer prevention. 
With few exceptions, there was also an absence of quality control throughout the country 
(170). A more recent study reported that HR-HPV test now is available in 5 provinces (167). 
 
Figure 6. Argentina and its provinces. 
https://commons.wikimedia.org/wiki/File:Ar
gentina_-_mapa_de_las_provincias.svg 
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Overall, there are large geographical inequalities in Argentina, with the age-standardized 
mortality ranging from a low 3.9 per 100,000 in the capital of Buenos Aires, to 18.9 per 
100,000 in the northern Formosa Province (169). There are also socioeconomic inequalities; 
indeed, the provinces with the highest cervical cancer burden in Argentina are also the 
poorest provinces (169, 173). Other studies have also confirmed such inequalities, with 
women of low socioeconomic status being screened less frequently than women of higher 
socioeconomic status. It has also been reported that these disparities are increasing in 
provinces with the highest burden of disease (174). Overall, it has been estimated that the 
current screening practice fails to cover 30% of Argentinean women, while another 40% are 
screened irregularly (175).  
 
2.4.1.3 HPV vaccination in Argentina 
The HPV vaccine was introduced to the national vaccination program in 2011, with the 
bivalent vaccine being administered free-of-charge to 11-year old girls (176). There is no 
subsidized catch-up vaccination, and vaccination for girls and women over the age of 11 is to 
be self-financed (177). In contrast to the poorly-functioning screening program, Argentina 
has a well-organized child vaccination program, with an uptake of childhood vaccines 
between 91-97%, which suggests that implementation of HPV vaccination should be feasible 
(178). Overall HPV prevalence is higher in South America than the global average (16% 
versus 12%) (16) and local Argentinean studies have presented even higher figures of 40-
47% in the Misiones and Formosa Province (179-181). The HPV 16/18 prevalence in ICC in 
Argentina is 77% (182), among the highest in the world (183) which suggests a potentially 
high impact of vaccination. Economic analyses have also found vaccination to be a cost-
effective approach (175, 184). Still, there were no studies on vaccination acceptance prior to 
the implementation of HPV vaccination. At the time of our studies, there was only one study 
on vaccination acceptance from Argentina, conducted in the Buenos Aires area (185). Thus, 
there was a particular need for studies from other parts of the country.  
 
2.4.2 Sweden  
2.4.2.1 Cervical cancer incidence and mortality in Sweden 
Sweden has had an organized population-based screening program since the 1960s, resulting 
in a dramatic reduction of cervical cancer incidence and mortality (67-69). The cervical 
cancer incidence in Sweden has declined by around 70% since the introduction of screening 
(66). However, the decline has stagnated over the last 10 years (186) and new data even show 
a 20% increase in the age-standardized cervical cancer incidence in Sweden between 2014 
and 2016 (187). The age-standardized incidence and mortality rate of cervical cancer is 8.7 
and 1.3 per 100,000, based on 2016 data from the National Board of Health and Welfare. 
This translates to approximately 540 new cases and 135 deaths each year (186). Cervical 
cancer is the 10th most common cancer among women of all ages in Sweden, but the third 
most common cancer in the age-group 15-44 years (168). In a nationwide Swedish study 
from 2008, it was found that two thirds (64%) of women diagnosed with cervical cancer and 
83% of women with advanced stages did not attend screening within the recommended 
screening interval. Non-adherence was found to double the risk of cervical cancer (OR 2.52, 
95% CI, 2.19 to 2.91) and quadruple the risk of advanced cancer (OR 4.82, 95% CI, 3.61 to 
6.44) compared to attendees (66). Another risk-group for cervical cancer in Sweden is 
women previously treated for CIN. In another nationwide study, it was shown that women 
with a history of CIN3 had a two- to six-fold risk of cervical and vaginal cancer compared to 
the general female population (standardized incidence ratio 2.34 95% CI: 2.18-2.50 and 6.82, 
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95% CI: 5.61-8.21, respectively). The risk persisted over time and remained increased after 
25 years (94).  
 
2.4.2.2 Organization of cervical cancer screening in Sweden 
The Swedish cervical cancer screening program began in 1964 and by 1977 it had nation-
wide coverage (66). The screening guidelines from the National Board of Health and Welfare 
have, until recently, recommended cytology screening every third year for women aged 23-50 
and every fifth year for women aged 51-60 (188). The screening program invites women to 
participate by invitation letters and midwives perform the smears at outpatient clinics, 
although opportunistic screening by gynecologists occurs as well. Both opportunistic and 
organized smears are registered and integrated into a national screening registry (189). In 
2016, the screening coverage was 82% for women aged 23–50 years and 84% for women 
aged 51–60, although there were large variations among counties. Relatively few women 
(8%) did not attend screening within a 6 years period (187). In most counties in Sweden, 
there had been a fee for cervical screening (ranging between 8-22€), while it has been free-of-
charge in some counties (189). As of January 2018, cervical cancer screening is free-of-
charge throughout the country (190).  
 
As mentioned above, the Swedish screening guidelines have recently been revised. In the 
new guidelines, primary HPV based screening is to be introduced (and has been introduced in 
some counties), every third year for women aged 30-49 (although with a supplementary 
cytology test for women aged 41) and every seventh year for women aged 50-64. Besides the 
shift to HPV-based screening, the upper age limit has also been raised. For women under the 
age of 30, cytology screening remains the method of choice (188), in accordance with 
international recommendations (82). However, it should be noted that the new Swedish 
screening recommendations differ slightly from the European guidelines in terms of 
frequency and the supplementary cytology test (82).  
 
2.4.2.3 HPV vaccination in Sweden 
The HPV vaccines were licensed in Sweden in 2006, but the implementation of HPV 
vaccines in the national school vaccination program was delayed until 2010 due to 
procurement issues regarding which vaccine should be included. It was decided to use the 
quadrivalent vaccine, and it is offered free-of-charge for girls aged 11-12 years. Recently, 
Sweden also shifted to a two-dose regimen of organized HPV vaccination (191). Catch-up 
vaccination is subsidized for females between ages 13-26, and have been offered free-of-
charge in some counties. For girls and women aged 13 years and above, the vaccine is still 
administered on a three-dose schedule. Boys are, thus far, not included in the national 
vaccination program and vaccination is not subsidized for males. In July 2017, The Public 
Health Agency of Sweden [Folkhälsomyndigheten], proposed that boys should also be 
included in the national vaccination program and is currently under evaluation (153).  
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3 AIMS 
3.1 GENERAL AIM 
The overall aim of this thesis is to contribute to cervical cancer prevention in countries with 
high and low burden of disease, by identifying barriers to HPV vaccination and cervical 
cancer screening and by exploring the long-term risk of recurrent disease in relation to 
surgical margin status among women previously treated for precancerous lesions.  
 
3.2 SPECIFIC AIMS 
3.2.1 Study I 
To examine acceptance of HPV vaccination among young adult women in Argentina, to 
explore the correlation of acceptance with cost and other factors, and to study perceptions of 
HPV vaccination.  
 
3.2.2 Study II 
To investigate maternal HPV vaccination acceptance among Argentinean mothers if 
vaccination was offered at no cost and if it was not free of charge, to explore correlates of 
willingness to pay for vaccination, and to study awareness of HPV and its related diseases 
and attitudes and perceptions of vaccination. 
 
3.2.3 Study III 
To explore barriers and facilitators of screening compliance in Sweden by; estimating time 
and travel costs and other direct non-medical costs of attending screening, examining 
screening compliance and correlates thereto, and by investigating knowledge of HPV, its 
related diseases and cervical cancer prevention and correlates of HPV knowledge. 
 
3.2.4 Study IV 
To investigate the long-term risk of recurrent or residual disease in relation to surgical margin 
status among women previously treated for high-grade dysplasia in Sweden. Secondary aims 
were to assess the risk with respect to age, the severity of the lesion and treatment modality. 
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4 MATERIALS AND METHODS 
4.1 STUDY SETTING, STUDY DESIGN AND STUDY POPULATION  
4.1.1 Study I and II 
Both studies were hospital-based cross-sectional surveys conducted in the Mendoza province, 
Argentina. Study I comprised 174 young adult women attending the Obstetrics/Gynecology 
Ward and the Outpatient Gynecology Clinic of the Diego Paroissien Public Hospital in 
Maipú, and Study II included 180 mothers attending Diego Paroissien Public Hospital or the 
Private Italian Hospital in the city of Mendoza. Eligibility criteria required the women in 
Study I to be between 18 and 30 years of age, while the mothers in Study II were needed to 
have at least one daughter aged 9-15 years. Women with known cervical malignancy or acute 
medical condition were not eligible for the studies. 
 
4.1.1.1 The Mendoza province 
The Mendoza province is located in the Cuyo region in the western-central part of Argentina 
with a total population of 1,885,000 inhabitants. According to national statistics, the mortality 
rate is slightly lower in Mendoza compared to overall figures from the country (7.3 versus 7.7 
per 100,000). Maternal and infant mortality rates are also lower with 23 compared to 39 per 
100,000 live births and 8.7 compared to 9.7 per 1,000 births, respectively. However, the 
illiteracy rate at 2.2% in Mendoza is slightly higher than the overall national rate of 1.9%. It 
has been estimated that 10.3% of the inhabitants in Mendoza do not have their basic needs 
met (173). A provincial program for cervical cancer prevention was established as early as 
1991 in the Mendoza province (192), which was before the initiation of a national prevention 
program (170). The Mendoza is also one of the few provinces in the country with quality 
control of laboratories, as well as computer registration of cytology testing. Still, it has been 
reported that only 25% of all pap smears in Mendoza are performed on the target age-group 
(170).  
 
4.1.2 Study III 
This was a descriptive population-based survey on 1510 women attending the cervical cancer 
screening program in five outpatient clinics located in Stockholm, Sweden. The outpatient 
clinics were located in the municipalities of Danderyd, Nacka, Sundbyberg, Stockholm City 
and Värmdö. Three clinics located in Jakobsberg, Botkyrka and Nynäshamn declined to take 
part in the study. The study invited women who were eligible for organized screening 
according to the national screening practices that were in use at the time of the study. Thus, 
women were required to be between 23 to 60 years of age and should not have had 
opportunistic screening recently.  
 
4.1.3 Study IV 
This Swedish long-term prospective cohort study comprised 991 women with a diagnosis of 
CIN2 or CIN3 who had been treated with cervical conization surgery at Karolinska 
University Hospital Huddinge between 2000-2007 and Solna between 2006-2007. Eligible 
participants had to have i) undergone a cervical conization, ii) a histopathological diagnosis 
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of CIN2/3 in the punch biopsy before the conization or in the cone biopsy, and iii) have 
information on margin status of the cone biopsy in their medical record. 
 
4.2 DATA COLLECTION 
4.2.1 Study I and II 
Using consecutive sampling, women were invited to participate from September to October 
2011 (Study I) and February to April 2012 (Study II). Potential participants were approached 
in waiting rooms and consultations offices at the gynecological clinic and on 
Obstetrics/Gynecology wards. Women were informed about the purpose of the study and the 
anonymity of their responses and those who agreed gave oral informed consent. Data was 
collected through surveys and structured survey-based interviews conducted by the first 
author (Alder) in Study I and by surveys alone in Study II (supervised by Gustafsson). One 
author (Alder or Gustafsson) was always present during the completion of surveys to answer 
questions or explain parts of the survey that the respondents did not understand.  
 
4.2.1.1 Questionnaire 
To the best of my knowledge, there were no validated questionnaires regarding HPV 
vaccination acceptance when our studies were conducted. The questionnaires used in the 
studies were adapted from those used in two large population-based studies on HPV-
vaccination on young adults and parents in Sweden (162, 163). In these studies, the 
questionnaires had been used for structured interviews as well as for web-based versions. 
They were developed at the Department of Medical Epidemiology and Biostatistics (MEB) 
Karolinska Institute in Sweden, and consent to use the questionnaires was given by one of its 
originators (Pär Sparén). The questionnaires were slightly modified to adapt it to the 
Argentinean population and thereafter translated to Spanish by one of the native Spanish-
speaking authors (Perinetti). The revised questionnaires were pilot tested before use, which 
resulted in some simplifications of the language in Study I, while kept unchanged in Study II. 
The questionnaire used in Study I was divided into six sections: demographics (part 1), sexual 
behavior (part 2), awareness of HPV-associated disease (part 3), general perception of 
vaccination (part 4), acceptance of HPV vaccination (part 5) and screening practices (part 6). 
In Study II the questionnaire contained five sections:  demographics (part 1), awareness of 
HPV-associated disease (part 2), general perception of vaccination (part 3), maternal 
acceptance of HPV vaccination for daughter (part 4) and perceptions on daughter’s sexual 
activity (part 5). As in the Swedish studies, all women received information on the role of 
HPV as a causative agent of cervical cancer before they answered questions on HPV 
vaccination acceptance.  
 
4.2.2 Study III 
The study was conducted between March 2013 and April 2014. Potential study participants 
were approached in waiting rooms of the outpatient clinics and those who agreed received 
surveys that they completed independently. Since one of the authors (Östensson or Alder) 
was present during the data-collection, it was possible to clarify misunderstandings and limit 
the number of missing responses. The average waiting and screening procedure time were 
measured on four separate occasions at two of the outpatient clinics on 197 women.  
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4.2.2.1 Questionnaire 
A questionnaire for the purpose of this study was constructed by the authors, based on 
recommendations from the UK Working Party on patient-reported costs (193) and 
questionnaires previously used to assess knowledge and attitudes on HPV (194-196). A 
pilot trial was conducted on women with various occupations, which resulted in a 
subsequent refinement of the questionnaire through a validation process. The questionnaire 
was divided into three sections: demographics (part 1), time and travel costs and other 
direct non-medical costs of attending screening (part 2) screening compliance and 
knowledge of HPV and cervical cancer screening.  
 
4.2.3 Study IV 
Women eligible for the study were identified in the medical record based on International 
Classifications of Diseases (ICD) codes (N87.1; CIN2 or D06.9; CIN3) and intervention 
codes (LDC03; conization with diathermy or laser, or LDC00; conization with knife). 
Clinical data was collected from medical records from 1 November 2015 until 30 November 
2017 and included: age, comorbidity, previous conizations, surgical modality, HPV status 
(when available), re-conizations and hysterectomy. Also, data from the pathology report was 
extracted on the diagnosis a) before treatment (based on histopathology or cytology), b) in the 
cone biopsy, c) during follow-up (cytology and histopathology), d) from re-conizations and 
hysterectomies, if any, and e) the margin status of the cone biopsy (positive or negative and 
endocervically or vaginally involved).  
 
4.3 DEFINITIONS AND ASCERTAINMENTS OF EXPOSURE AND OUTCOME 
4.3.1 Study I and II 
In both studies, acceptance of HPV vaccination (the outcome variable) was classified into 
three categories (unsure/unwilling to vaccinate, even if vaccination was free, willing only if 
vaccination was free and willing even if vaccination was not free). 
 
4.3.2 Study III 
Non-compliance with screening was defined as not attending screening within one year from 
the initial invitation. Knowledge of HPV and cervical cancer screening was assessed by the 
respondent’s agreement with 17 correct facts. The answers were scored as 0 if the respondent 
did not agree or did not know, while agreement was scored as 1. Costs were expressed in 
2012 prices and converted from Swedish kronor (SEK) to Euro (EUR) based on the average 
exchange rate for 2012 (1 EUR = 8.7 SEK). Travel cost for car users was estimated at EUR 
0.45 per kilometer, on the basis of a formula developed by the Swedish Automobile 
Association, which included fuel, taxes, services and other costs (197). Travel cost for public 
transport was estimated at EUR 0.13 per kilometer, based on the cost of a 30-day public 
travel card (EUR 91.6), which is used by most travelers (70% of all ticket sales in Stockholm) 
(198) and mean distance to and from work by public transport  (i.e. 24 kilometer) (199). 
Travel cost for taxi was based on the women’s reported mean cost. Transportation for 
walkers and cyclist were valued at no costs. It was assumed that companions (if any) had the 
same travel cost as the screening participant (except when traveling together by car or taxi). 
Activities before and after screening were categorized into: work, education, leisure activity 
and dropping off or picking up children at school or child care. Costs related to arranged child 
care to facilitate screening attendance were estimated based on the women’s reported mean 
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cost. The value of time off work for participants or their companion was estimated at EUR 
29.9 per hour based on the Swedish gross wage rate (200). If it was not needed to take time 
off work, time was estimated at EUR 12.4 per hour, which is based on the value of non-
working time used when assessing Swedish public transport projects (201, 202).  
 
4.3.3 Study IV 
A negative margin was defined by the absence of high-grade dysplasia, CIN2 or worse, in the 
resection margin or by absence of CIN2 or worse in the endocervical curettage, performed 
after the conization. To verify that the primary exposure of interest – the margin status– was 
correctly assessed, all surgical pathology reports were re-viewed by one of the authors 
(Alder) and all uncertain cases were assessed by two authors (Alder and Andersson, the latter 
a senior gynecologist). Comorbidity was defined in terms of conditions likely to interact with 
the acquisition or persistence of HPV or development of CIN (i.e. autoimmune disorders, 
HIV, hepatitis B/C, malignancy, diabetes, genetic disorders and organ transplantation). HR-
HPV positivity included also women infected with a probably carcinogenic HPV type, as 
many probably carcinogenic HPV types now have been reclassified as carcinogenic. The 
outcome was a histopathological diagnosis of residual or recurrent CIN2+ (CIN2, CIN3, AIS 
or worse, vaginal intraepithelial neoplasia (VAIN), vaginal cancer, or recurrence to the pelvis 
or other location). If both glandular and squamous components were reported, it was 
classified based on the glandular component (i.e. AIS and CIN was coded as AIS and ADC 
and SCC was coded as ADC). Information on residual or recurrent CIN2+ was obtained from 
the medical record and by linking the study women to the Swedish National Cervical 
Screening Registry (203), as described below.  
 
4.4 OTHER METHODS 
4.4.1 Swedish National Cervical Screening Registry  
In Study IV, all women were linked to the Swedish National Cervical Screening Registry 
based on their unique registration numbers to obtain data on recurrent or residual disease 
(outcome). The Swedish National Cervical Screening Registry analyses and evaluates the 
national cervical cancer screening program. Their annual reports include information on 
screening coverage, invitations, laboratory reporting and other quality assessments. The 
registry has 100% coverage of all cervical cytology and histopathology tests in Sweden and 
thus provided complete data on these endpoints until Dec 31, 2016. Further, it has a 
nationwide coverage and provided information also on women who had migrated within the 
country, as data are linked to the unique registration numbers. As of 2015, the registry also 
includes data on all HPV tests performed throughout the country (187). Such information 
on the study women was also extracted from the registry, when available.  
 
4.4.2 Conization procedures 
In Study IV, all women were treated by conization. The treatment modality in use at 
Karolinska Huddinge at the time of the surgeries was diathermy; mainly loop excision 
electrosurgical procedure using a Contoured loop excision of the transformation zone (C-
LETZ) electrode (Utah Medical Products Inc., Midvale, UT, USA), while laser treatment was 
in use at Karolinska Solna (carbon dioxide laser (CO2 laser)).  
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4.4.3 HPV tests 
In Study IV, some women were HPV tested before treatment and during follow-up. The 
HPV tests in use at Karolinska at the time of the study were Hybrid Capture® 2 HPV DNA 
Test™ (QIAGEN Inc., Gaithersburg, MD, USA (previous Digene Corp.)), Linear Array® 
HPV Genotyping Test (Roche Molecular Systems Inc., Alameda, CA, USA) and Cobas 
4800 (Roche Molecular Diagnostics, Pleasanton, CA, USA). Information on HR-HPV-
status of the study women was also obtained from the Swedish National Cervical Screening 
Registry (203), as described above.  
 
4.5 STATISTICAL ANALYSES 
In all studies, data frequencies of variables were calculated using SPSS (IBM, Armonk, NY, 
USA, IBM version 20.0 (Study I and II), IBM 21.1 (Study III) or IBM 25.0 (Study IV)). P-
values were based on the Wald-Chi square or Fisher’s exact test or Monte Carlo estimates 
when numbers were too small (n>5). All p-values were two-sided and <0.05 was considered 
statistically significant.  
 
4.5.1 Study I  
A multinomial cumulative logistic regression was used to explore potential correlates of HPV 
vaccination acceptance using SAS® (System 9.1; SAS Institute, Cary, NC, USA), with 
unsure/unwilling to vaccinate, even if vaccination was free, as the reference category.  Exact 
estimates and p-values were obtained when frequencies were too low for multinomial 
regression. Statistically significant covariates from the multinomial regression (based on p-
value <0.05) were included in the multivariable model, which adjusted for all other variables 
in the analysis.  
 
4.5.2 Study II 
Acceptance of HPV vaccination was classified into three categories, as described above. 
However, due to the fact that only a few women were unsure or unwilling to vaccinate their 
child, all women that answered such were excluded from the analysis on potential correlates 
of vaccination acceptance (n=18). Therefore, a binomial logistic regression model was 
performed using SAS® (System 9.4; SAS Institute, Cary, NC, USA). Thus, this analysis was 
restricted to investigate correlates of willingness to pay for HPV vaccination, compared to 
willingness if vaccination was free. All statistically significant correlates from the binomial 
regression were included in the mutually-adjusted multivariable analysis. 
  
4.5.3 Study III 
A power calculation was performed before the study, which determined that a sample size of 
1500 women would provide a power of 0.976 to detect a 10% difference in the proportion of 
correct answers on knowledge questions between age groups. Cronbach’s alpha coefficient 
was used for internal reliability evaluation and an alpha ≥0.70 was considered acceptable. 
Percentages were based on only those who responded (thus, missing data was not included). 
  31 
Differences in mean transport costs by mode of travel, travel time and travel distance were 
analyzed by one-way analysis of variance (one-way ANOVA) at 5% level of significance, 
with a Bonferroni correction. Differences in sociodemographic characteristics of the study 
women were compared to the general female population in Sweden (based on official 
statistics from Eurostat (204)) using the Z-test. This was also used for comparing differences 
in HPV knowledge between age groups. In order to investigate correlates of HPV knowledge 
and screening compliance, a binomial logistic regression analysis was performed. Correlates 
of HPV knowledge was obtained by using a binary dependent variable based on the median 
knowledge score (≥5 or <5). By using a manual backward stepwise procedure, non-
significant variables were removed from the model or kept in the analysis if they changed the 
width of the other variables CIs by ≥10%  
 
4.5.4 Study IV 
A Kaplan–Meier analysis was performed to plot curves of residual or recurrent CIN2+ among 
margin positive or negative women, respectively, and the log rank test was used to compare 
the distributions. The follow-up time was measured from the date of the first surgery until the 
date of CIN2+, death or deregistration or until end of study, Dec 31, 2016. Women with 
cervical cancer (SCC/ADC) in the cone biopsy were not included in the follow-up analysis. 
Cox proportional hazards models were used to assess HRs for the association between margin 
status and residual or recurrent CIN2+, adjusting for comorbidity, age at surgery, the severity 
of the lesion, treatment modality and previous conization. An additional Cox regression 
analysis was undertaken on margin status and recurrence/residual disease, stratified by HPV-
status. Due to the limited sample, it was not possible to perform an HPV stratified analysis 
also on subdivided margin status. 
 
4.6 ETHICAL CONSIDERATIONS 
 
4.6.1 Study I and II 
Study I was approved by the Ethics Review Committee of the Diego Paroissien Public 
Hospital and Study II by the Ethics Review Committees of the Diego Paroissien Public 
Hospital and the Private Italian Hospital. Oral informed consent was obtained from all 
participants before administering the surveys/conducting the interviews.  
 
4.6.2 Study III 
Approval from the Regional Ethical Review Board of Stockholm was obtained, which 
determined that written informed consent was not required (Dnr: 04-679/3, 2010/944-32, 
2012/1892-32). Both written and oral information about the purpose of the study was 
provided to all potential study participants and oral informed consent was obtained from all 
participants prior to the administration of the surveys.  
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4.6.3 Study IV 
The study was approved by the Regional Ethical Review Board of Stockholm, which 
determined that informed consent from the participants was not required (Dnr: 168/03, 2004-
679/3, 2010/944-32, 2013/763-32, 2014/2255-31/5 and 2017-2007/32). However, all women 
that had decided to block access to their medical record were excluded from the study.  
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5 RESULTS 
5.1 STUDY I 
5.1.1 Characteristics of study sample 
In all, 228 women were invited to participate in the study, of which 200 (88%) agreed. Of 
these, 174 (87%) responded to the survey by interviews, while 26 (13%) responded by 
written surveys. Due to a high frequency of missing data of the written surveys, only women 
administered by interview were included in the study. Thus, the final study sample consisted 
of 174 women. The median age of the women was 23 years. Most women were married or in 
a relationship (84%) and 71% were housewives/unemployed. Half the sample (50%) had an 
annual income of <170 EUR and almost two-thirds (61%) reviewed welfare and had less than 
a high school education (65%). 
 
5.1.2 Acceptance of HPV vaccination  
Acceptance of HPV vaccination was 95% if vaccination was free and 75% stated that they 
were also willing to pay for vaccination. Few (5%) were unsure/unwilling to be vaccinated 
against HPV. Among participants willing to pay for vaccination, the median price women 
were willing to pay for vaccination was 11.50 EUR (per dose).  
 
5.1.3 Correlates of HPV vaccination acceptance 
General believes in vaccination safety and vaccine effectiveness was statistically significantly 
positively associated with acceptance of HPV vaccination, irrespective of costs in the 
univariate analysis. Also based on results from the univariate analysis, negative associations 
were found between receiving welfare as well as not having heard of condyloma and 
willingness to pay for vaccination, however, CIs were wide. In the multivariable analysis, 
after adjustment for all other variables in the analysis, general believes in vaccination safety 
remained statistically significant. Women who did not regard vaccination as safe were 
statistically significantly less willing to accept vaccination if it was free (OR: 0.07, 95% CI: 
0.01-0.49), and if it was not free (OR: 0.15, 95% CI: 0.03-0.88). Also being a welfare 
recipient remained statistically significantly negatively associated with vaccination 
acceptance if vaccination was not free (OR: 0.11, 95% CI: 0.11-0.99) in the multivariable 
analysis (Table 2). 
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Table 2. Multivariable analysis on acceptance of human papillomavirus (HPV) vaccination with 
‘unsure/unwilling even ifvaccination was free’ as reference category.a
 
 
 
5.1.4 Perceptions of HPV vaccination 
Nearly half the women (44%) were under the impression that HPV vaccination would 
provide complete protection against cervical cancer. The majority (74%) stated that they 
would not practice more unsafe sex following HPV vaccination, while one in ten (10%) 
believed they would. The main reasons for abstaining from HPV vaccination were concerns 
regarding side-effects (54%) and concern about the protective effect (16%). 
 
5.1.5 Knowledge of HPV and cervical cancer and screening practices 
Almost all women (95%) were aware of cervical cancer screening prior to the study, eight out 
of ten (81%) were aware of cervical cancer, 58% were aware of HPV and 24% were aware of 
condyloma. More than half (55%) had ever participated in screening and participation rate 
was found to increase with age; 29% in women aged 18-19 years and 84% in women aged 
26-30 years. Only 4% of the non-participants in screening stated that they would not 
participate at all in the future if they were vaccinated against HPV. However, 24% of the 
previously screened women believed that they would participate less frequently. 
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5.2 STUDY II 
5.2.1 Characteristics of study sample  
Of the 211 mothers  invited to the study, 20 (10%)  did not agree to participate and another 11 
(5%) were excluded due to a high frequency of missing data. The final sample thus 
comprised 180 women, of which the majority were recruited from the public hospital (86%) 
and 14% from the private hospital. The median age of the women was 37 years (range 26-59 
years). Most mothers were married or in a relationship (79%), more than half were 
housewives (57%) and nearly half had four or more children (45%). Only one third (27%) 
had high school education or above. 
 
5.2.2 Maternal HPV vaccine acceptance  
Nine out of ten (90%) mothers stated that they were willing to vaccinate their child against 
HPV. Sixty percent stated that they would do so even if vaccination were not free. Only three 
mothers were unwilling to vaccinate even if vaccination was free. The mean price that 
mothers were willing to pay for vaccination was 23 EUR (per dose). Still, 21 mothers stated 
that they would vaccinate their daughters irrespective of costs.  
 
5.2.3 Correlates of willingness to pay for vaccination 
Higher education, being gainfully employed, having a higher disposable household income 
and being aware of cervical cancer prior to study were all statistically significantly associated 
with willingness to pay for HPV vaccination in the univariate regression analysis. Also, there 
were tendencies of higher vaccination acceptance even if vaccinating was not free, among 
older women and women with previous HPV awareness, although it did not reach formal 
statistical significance. Similarly, mothers who were unsure about vaccine safety in general 
seemed less willing to pay for vaccination but this was neither statistically significant. All 
variables that did reach statistical significance were included in the mutually adjusted 
multivariable model. In this analysis, being gainfully employed (OR: 2.54, 95% CI: 1.01-
6.38), having a higher disposable household income (OR: 3.28, 95% CI: 1.36-7.94) and being 
aware of cervical cancer prior to study (OR: 3.22, 95% CI: 1.02-10.14) remained statistically 
significantly associated with willingness to pay for vaccination.  
 
5.2.4 Perceptions of HPV vaccination 
Almost half (46%) believed their daughter to be fully protected against cervical cancer after 
vaccination, while few (10%) believed that they would not. Half of the women (54%) 
considered vaccination to be safe in general while 12% believed it to be not so safe/unsafe. 
Further, 65% considered vaccines in general to be effective, while few (5%) regarded 
vaccination as not so effective/ineffective. The concerns related to HPV vaccination included 
vaccine efficacy (41%), side-effects (27%) and whether additional doses were needed (17%).  
A large proportion (39%) of the mothers were concerned as to whether their daughters would 
be more likely to engage in sexual activity following HPV vaccination. Still, most women 
(64%) stated they would not let this concern make them abstain from HPV vaccinating their 
daughter.  
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5.2.5 Awareness of HPV and its related diseases  
The majority of the mothers had previous awareness of cervical cancer (83%), just over half 
were aware of HPV (56%) and 39% were aware of condyloma before the onset of the study. 
Among those aware of HPV, 64% thought it could cause cervical cancer.   
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5.3 STUDY III 
5.3.1 Characteristics of study sample 
Among the invited women, around 2% declined to participate and the final study sample 
comprised 1510 women. The study women had a statistically significant higher level of 
education and income in comparison to the general female population in Sweden, the 
Stockholm County and all municipalities included in the study except Danderyd (p <0.01).  
 
5.3.2 Travel characteristics, time and travel costs and other direct non-
medical costs 
One third of the women went to and from screening using public transport (30%), another 
third (28%) went by car and yet another third (27%) walked. Among those who went by 
public transport, most women (n=628) paid with a 30-day pass and few (n=40) paid with a 
zone ticket (cost range: EUR 4-6). The majority came directly from their homes (86%) and 
12% came from work. After the clinic visit, 60% of the women stated that they were traveling 
to work, while 28% were going back to their home. Mean distance traveled to and from the 
clinic was 6.4 and 11.4 km, respectively, with a mean total distance of 17.8 km. Average 
travel times to and from the clinic were 18 and 26 minutes (not including time related to 
errands on the way), resulting in a total travel time of 44 minutes. When comparing mean 
travel time, travel distance and travel costs by mode of transport, all differences were 
statistically significant.  
 
The estimated average waiting time was 10 minutes and the estimated time of screening 
procedure was 13 minutes, resulting in a total time of 23 minutes/visit. Just over half (53%) 
the women took time off work to attend screening, with a mean time of 147 minutes. Twelve 
percent had a companion with them to screening (most were accompanied by their partner). 
A large share of the companions (59%) had also taken time off work, with a mean time of 
113 minutes. Relatively few women (3%) had arranged child care to facilitate screening 
attendance. Of those 42 who did, 35 incurred out-of-pocket costs related to this (mean time: 
168 minutes, estimated cost: EUR 78.4). Mean total travel cost to the screening clinic was 
estimated at EUR 1.9 and 2.9 from the clinic. Estimated mean total cost (time and travel costs 
and other direct non-medical costs) per screening attendance was EUR 50.8. If also including 
companions (if any) this amounted to EUR 55.6 per attendance. 
 
5.3.3 Knowledge of cervical cancer screening and HPV  
Many women (69%) knew that the purpose of screening was to prevent cervical cancer while 
one third (31%) were under the impression that its purpose was to prevent all types of 
gynecological cancers. HPV knowledge was compared between age groups, and a 
statistically significantly higher level of knowledge was found in younger women aged 29 
years or below compared to women aged 30 to 49 years in regards to HPV being transmitted 
sexually (51% versus 39%), HPV infecting both sexes (30% versus 24%) and HPV being 
most common among young (37% versus 27%). This was also found for knowledge on HPV 
being mostly asymptomatic (41% versus 35%), that persistent infection with HPV can lead to 
dysplasia (54% versus 49%) and that HPV can cause condyloma (24% vs 22%). Among all 
women, 64% had knowledge on the existence of HPV vaccines; but less (41%) knew that it is 
most effective if administered prior to sexual debut and that HPV vaccination does not 
provide complete protection against all HPV types (34%). Only 7% of women regarded their 
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knowledge of HPV and cervical cancer as good, while the corresponding figure was slightly 
higher for knowledge of cervical cancer prevention (16%).  Many of the respondents (63%) 
wanted to obtain additional information on HPV from a midwife or a physician and 52% 
wanted to receive information through brochures.  
 
5.3.4 Screening compliance  
In all, 44% of the women stated that they were non-compliant to screening. Among those, 
just over half (51%) expressed that this was due to difficulties in taking time off work, 
another 33% were “too busy” and 16% stated other reasons (e.g. fear of gynecological 
examination, previous negative experiences, menstrual period and pregnancy).  
 
5.3.5 Correlates of screening compliance and HPV knowledge 
There was a statistically negative association between screening compliance and need to take 
time off work, and screening compliance was found to decrease with increasing number of 
hours needed (Table 3). The OR was 0.62 (95%CI; 0.43-0.89) for taking one hour off work, 
0.46 (95% CI: 0.34-0.62) for two hours off work and 0.27 (0.18-0.39) for three hours off 
work compared to women not taking time off work. Taking four hours or more off work was 
also statistically significantly associated with lower screening compliance compared to not 
taking time off work (OR 0.40, 95% CI: 0.27-0.60), although the OR was not lower than OR 
for women taking three hours off work. Bringing a companion to screening was also 
statistically significantly negatively associated with screening compliance (OR: 0.51, 95% 
CI: 0.36–0.71), while HPV knowledge was positively associated (OR 2.4, 95% CI: 1.91–
3.02). 
 
Higher education was statistically significantly associated with HPV knowledge and 
increased with higher level of education; OR for women with high school or equal was 3.23 
(95% CI: 1.56–6.66) and 8.67 (95% CI: 4.19–17.93) for women with more than high-school 
education compared to women with less than high school education. Lower age was also 
statistically significantly associated with screening compliance, with OR of 1.9 (95% CI: 
1.01-3.55) in women aged 24 years or below and 1.89 (95% CI: 1.09–3.28) in ages 25-29 
years, compared to women aged 55 years or above. Knowledge was also higher in women 
aged 45-54, compared to women aged 55 years or above, while no statistically significant 
differences could be shown in women aged 30-44 years.  
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Table 3. Correlates of human papillomavirus (HPV) knowledge and screening compliance for 1510 women 
attending the clinic-based cervical cancer screening program in Sweden. 
 
 
 
 40 
5.4 STUDY IV 
5.4.1 Characteristics of study sample 
Of the 1075 study women, 991 met the inclusion criteria of which 721 women had undergone 
treatment at Karolinska Huddinge and 270 at Karolinska Solna. At the end of the study, 4% 
were deceased and 2% were deregistered, mainly due to migration. The median age was 33 
years (range 19-94 years). The majority of women had no underlying comorbidity (91%). 
Few (3%) had previously been treated with conization. The most common reason for 
conization was CIN3 (62%), followed by CIN2 (30%) and CIN1 (5%). The majority was 
treated by diathermy (73%) and 27% by laser. Hospital site, age at surgery, treatment 
modality, previous conization treatment and the reason for conization treatment were all 
statistically significantly associated with margin status.  
 
5.4.2 Margin Status of the cone biopsy 
In all, 65% of cone biopsies had negative margins, while 31% were incomplete at one or 
more margins, or of uncertain margin status, and additionally 4% were not eligible for margin 
status evaluation, due to absence of dysplasia in the cone biopsy. Of the samples with positive 
or uncertain margin status, 13% affected the endocervical margin, 7% the vaginal margin, 6% 
both margins and in another 4% it was unclear from the report which margin that was 
affected. The histopathological diagnosis of the cone biopsies were CIN3 in 63%, CIN2 in 
22%, CIN1 in 7% and SCC/ADC in 3% of cases. There was a statistically significant 
association with the severity of lesion and margin involvement (p<0.001).  
 
5.4.3 Re-conization, hysterectomy and follow-up HPV 
One in ten women (11%) underwent re-conization treatments. There was a larger share of 
women with involved margins in the re-treatment group compared to those without re-
treatment (51% and 28%, p<0.001). One third underwent re-conization due to CIN3 (30%), 
another third due to CIN2 (27%) and one forth due to CIN1 (25%). Half the re-conization 
biopsies showed only CIN1 or no dysplasia (51%), while 46% showed CIN2-3. Only every 
fifth women (20%) were HPV tested at any time during follow-up and 9% were HR-HPV 
positive. One in ten women (9%) underwent a hysterectomy during follow-up. Reasons for 
hysterectomy were residual or recurrent dysplasia (33%), treatment for SCC/ADC (22%) and 
other reasons (24%). Notably, another 21% underwent hysterectomy only on the basis of 
involved margins in the previous cone biopsy.  
 
5.4.4 Follow-up and outcome 
Median follow-up time was 10 years (range 0-16 years). Most women (88%) were followed 6 
to 16 years. In total, 12% of the women were diagnosed with a histologically confirmed 
residual or recurrent CIN2+ during follow-up (all 25 women with SCC or ADC in the first 
conization were excluded from this analysis). Nearly half (46%) of those who relapsed did so 
within the first year, while 16% relapsed at least 5 years later. There was a higher proportion 
of involved margins in the recurrence group compared to the non-recurrence group (51% 
versus 26%, p<0.001). Only 1% was diagnosed with cervical cancer during follow-up. There 
was a tendency toward a higher proportion of involved margins in the cervical cancer group; 
however, it was not statistically significant (p=0.074).  
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5.4.4.1 Kaplan-Meier analysis 
The Kaplan-Meier curve of the association between margin status and time to residual or 
recurrent CIN2+ is illustrated in Figure 7A, and according to subcategorized levels of margin 
status in Figure 7B. A statistically significant difference was observed according to margin 
status with the log rank test in both analyses (p<0.001). 
 
 
 
 
 
 
Figure 7.A. Kaplan-Meier plot of residual or recurrent cervical intraepithelial neoplasia or worse (CIN2+) 
according to margin status.  B. Kaplan-Meier plot of residual or recurrent CIN2+ according to different levels 
of margin status. 
 
 
5.4.4.2 Cox proportional hazards models 
Involved margins were positively associated with residual or recurrent CIN2+ (HR 2.68, 95% 
CI: 1.82-3.94 p<0.001) in the multivariate Cox model (adjusting for comorbidity, age at 
surgery, the severity of the lesion, treatment modality and previous conization procedures), 
(Table 4). Other covariates associated with risk of CIN2+ were comorbidity (HR 2.29, 95% 
CI: 1.39-3.75), and previous conization procedure/-s (HR 2.28, 95% CI: 1.07-4.85). The 
subcategorized levels of margin status also remained statistically significant in the adjusted 
Cox regression analysis (p<0.001, Table 5). An almost three-fold risk of residual or recurrent 
CIN2+ was shown among women with involved endocervical margins (HR 2.74, 95% CI: 
1.69-4.45) and in women with involved margins though uncertain if endocervical or vaginal 
(HR 2.84, 95% CI: 1.39-5.80) and even higher risks when both margins were involved (HR 
4.97, 95% CI: 2.84-8.69) compared to women with negative margins. No statistically 
significant positive association with residual or recurrent CIN2+ was found when only the 
vaginal margin was involved. Also in this model, comorbidity and previous conization 
procedure/-s were statistically significant covariates.  
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Table 4. Cox regression model for Hazard Ratio (HRs) of residual or recurrent cervical intraepithelial neoplasia 
or worse (CIN2+)a. 
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Table 5. Cox regression model for Hazard Ratio (HRs) of residual or recurrent cervical intraepithelial neoplasia 
or worse (CIN2+) according to subcategorized levels of margin status a. 
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An additional Cox regression model, stratified by HPV-status, was performed to further 
analyze the association between margin status and recurrent/residual disease (Table 6). 
Margin status remained statistically significant when no follow-up HPV test was taken 
(p<0.001).  There was also a tendency towards increased risk among margin positive women 
who were HR-HPV positive during follow-up, although it did not reach statistical 
significance (2.21, 95% CI: 0.98-5.01, p=0.031).  
 
 
Table 6. Cox regression model for Hazard Ratio (HRs) of residual or recurrent cervical intraepithelial neoplasia 
or worse (CIN2+) stratified by HPV statusa. 
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6 DISCUSSION 
6.1 STUDY I 
6.1.1 Main findings and interpretations 
We found that acceptance of HPV vaccination was very high in this Argentinean setting; with 
95% of young adult women stating that they would accept vaccination. The majority (75%) 
expressed that they were also willing to pay for vaccination. The latter is an especially 
important finding since there is no subsidized catch-up vaccination among young adult 
women in Argentina. However, the price these women stated that they were willing to pay for 
vaccination was four times lower than the actual price (205). Also, we found that women who 
received welfare were less willing to pay for vaccination, although the CI was wide but still 
reached a significant level. Taken together, these findings could implicate that cost could 
pose a barrier to vaccination of young adult women in this setting. 
 
Another important finding was that acceptance of HPV vaccination was lower among women 
who did not regard vaccines as safe in general. Also, half the respondents stated that the main 
reason to abstain from vaccination was concerns regarding side-effects. These findings 
suggest that it is important to ensure the safety of HPV vaccines in order to achieve a high 
vaccination uptake. A common misconception was that HPV vaccination would provide 
complete protection against cervical cancer, which it does not. This needs to be clarified to 
potential vaccine receivers. Also, one in ten women stated that they would practice more 
unsafe sex if they were vaccinated, which also needs to be targeted.  It is therefore important 
to develop public education campaigns.  
 
It was very encouraging that almost all women were aware of cervical cancer screening and 
eight out of ten women were also aware of cervical cancer. It should be noted that the 
commonly used name for cervical cancer screening in Argentina is Papanicolaou, while the 
word for cervical cancer is cancer de cuello uterino, which could explain this discrepancy. 
Overall awareness of HPV was also surprisingly high (58%) among our study women. 
However, this high figure relates only to awareness, i.e. having heard of HPV. 
 
6.1.2 Comparisons with other studies 
Overall acceptance of HPV vaccination was higher in our study compared to findings from 
the only existing study on HPV vaccination of adult women from Argentina (95% versus 
75%, respectively). That study was conducted in the Buenos Aires area in 2012, and 
investigated 1,200 mothers’ willingness to vaccinate themselves or daughters (185). Our 
higher findings on acceptance could be influenced by the fact that all women received 
information on the role of HPV as a causative agent of cervical cancer before they answered 
questions on HPV vaccination acceptance. This could demonstrate the importance of 
providing adequate information about the vaccine. Further, our study included only women 
aged 30 years or below while the other study included women up to age 49 years. Several 
studies have observed a negative association between higher age and acceptance (161, 163). 
Also, the women in our study had a lower level of education, which has been reported to be 
associated with higher vaccination acceptance among young adults (163).  
 
As many as three out of four women in our study were willing to pay for vaccination, which 
is higher than corresponding figures from Sweden, despite our study women’s limited 
economic means. In the Swedish study, only 34% of young adult women were willing to pay 
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for vaccination (163). Reasons for this might be differences in attitudes regarding government 
expenditure as well as differences in cervical cancer burden between the countries. Still, the 
importance of cost in relation to high vaccination acceptance has been shown in several other 
studies (160, 161, 163). Also, in the Buenos Aires study (185) cost was found to constitute a 
barrier to HPV vaccination and was the second most common reason for non-vaccination. 
The finding that acceptance of HPV vaccination was lower among women who do not regard 
vaccines as safe in general has also been shown in several other studies (160, 162, 163). The 
misconceptions of HPV vaccination were higher in our study compared to findings in other 
studies. Almost half of our women believed HPV vaccination to provide complete protection 
against cervical cancer, which is considerably higher compared to European findings of 7-8% 
(163, 206). Cervical cancer screening awareness was equally high in a previous Argentinean 
study from 2003, in which 93% were aware of it (207). In a recent Argentinian study on 
knowledge of HPV on almost 1,300 respondents, a majority (62%) had knowledge of the 
relation between HPV and cervical cancer (208). This is very promising and could suggest an 
increased knowledge among the population. In our study less (58%) were aware of HPV, i.e. 
knew that it existed, while having knowledge of HPV being a causative agent of cancer is a 
higher level of knowledge. 
 
6.1.3 Methodological considerations and validity 
A major strength of this study is that it is one of few studies on HPV vaccination acceptance 
from Argentina. Also, it is the only study from a non-metropolitan part of the country, which 
is important as cervical cancer burden varies widely throughout the country, and Buenos 
Aires is one of the province with the lowest cervical cancer burden (169). Another strength is 
that all included women in this study were administered by the structured interview-
technique, which resulted in almost no missing data. Furthermore, the non-participation rate 
was good (76%), even though we excluded all written surveys.    
 
An important methodological aspect one has to consider is the validity of the survey. At the 
time of the study, there were no validated questionnaires on HPV vaccination acceptance. 
However, the survey used in this study was adapted from a questionnaire used in a large 
Swedish population-based study (17), as described more in detail in the methods section. It 
was developed at MEB together with their questionnaire advisory group and used on more 
than 10,000 respondents in the Swedish study. We also performed a pilot trial of our 
translated and slightly modified version that did not reveal any obvious misconceptions. 
Overall, it was a well-developed, comprehensive survey, used on a large number of women 
prior to our study, which we consider to be a strength in our study. It was noted in our study, 
that a recurring spontaneous concern was high cost, which was not listed as a multiple-choice 
option. It is likely that more women would have stated this as a concern if it had been 
included as a multiple-choice option. Also, the predictive validity of our findings on 
vaccination acceptance can be discussed. This study examined theoretical acceptance, which 
may not be transferable to actual uptake. This could be especially important for willingness to 
pay for vaccination, especially since the actual price was not specified. Further, the results 
could have been influenced by the fact that we explained the causative role of HPV in 
cervical cancer development. Also, women might have considered acceptance to be the 
socially desirable response, which could have influenced our results. The latter could be 
especially important as the surveys were administered by interview. Nowadays there are 
several validated scales for HPV vaccine surveys (209, 210), to reduce methodological issues 
related to the design of questionnaires. 
 
There are also several general limitations to this study. The cross-sectional design, small 
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sample size and the homogeneity of the study population limit the generalizability of our 
findings. Also, there are several potential sources of selection bias including the limited 
geographical area represented by the inclusion of women from only one hospital and that all 
women had actively sought health care.  
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6.2 STUDY II 
6.2.1 Main findings and interpretations 
Maternal acceptance of HPV vaccination was very high both when free of charge (90%) and 
when it was not free (60%). The high level of acceptance is of major importance for a country 
like Argentina with a high burden of cervical cancer and insufficient cervical cancer 
screening coverage. We found that women who were gainfully employed and had a higher 
disposable household income were more willing to pay for vaccination, as were women with 
prior awareness of cervical cancer. The finding of an association between employment status 
and income with willingness to pay for vaccination suggests that cost could be an obstacle to 
catch-up vaccination. There is no subsidized catch-up vaccination for girls over the age of 11 
years in Argentina, and vaccination is to be self-financed by the families.  
 
Also, women with prior awareness of cervical cancer were more willing to pay for HPV 
vaccination, indicating the importance of improving awareness of HPV and its related 
diseases. Our findings showed that four out of five mothers were aware of cervical cancer 
prior to the study, which is equally high as in Study I. Also, awareness of HPV was equally 
and surprisingly high as in Study I, with more than half (56%) having heard of it. Among 
those aware of HPV, a very high figure (64%) believed it could cause cervical cancer.   
 
A very discouraging finding was that only half the mothers believed vaccination to be safe in 
general and only a slightly higher number found vaccination to be effective in general. Also, 
41% expressed concerns about vaccine efficacy and almost one third regarding side-effects. 
In our study, there was a tendency towards lower acceptance of vaccination among mothers 
with general disbelieves in vaccination safety; however, it did not reach formal statistical 
significance. Still, belief in vaccination safety was found to be correlated with acceptance in 
our previous study, both when vaccination was free of charge and when it was not. Several 
other studies have also found beliefs in vaccination safety to be an important factor of HPV 
vaccination acceptance (160, 162, 163). It is thus important to target these safety issues in 
order to achieve high vaccination uptake.  
 
Almost half the mothers incorrectly believed their daughter to be fully protected against 
cervical cancer after vaccination, while few believed that they would not. Also, a large 
proportion of the mothers were concerned as to whether their daughters would be more likely 
to engage in sexual activity following HPV vaccination. Still, most women stated they would 
not let this concern make them abstain from HPV vaccination.  
 
6.2.2 Comparisons with other studies 
Many studies from low-income settings have shown equally high figures on parental 
vaccination acceptance (109, 211-214). On the contrary, a lower maternal acceptance rate 
(75%) was found in the study from Buenos Aires (185), as discussed in Study I.  A more 
recent Argentinean study on HPV vaccination acceptance from the Chaco province found an 
even lower parental acceptance rate of just below 50% (215). Studies on the actual uptake of 
HPV vaccination after the implementation of HPV vaccine to the organized school 
vaccination program are scarce. It has been reported that full-course vaccination coverage 
was only 50% in the 2000 birth cohort (118), and even lower local figures have been 
presented, with an uptake of only 25% in the Chaco province based on data from 2012 (215).  
 
A concern in connection with the launching of vaccines was that vaccinated girls might 
engage in more sexual risk-taking. Among our study women, this was a quite common 
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concern. Several studies, among them a large study from Norway (216), have shown that the 
subsequent sexual behavior among HPV vaccinated individuals is unchanged, and no 
different compared to unvaccinated. 
 
6.2.3 Methodological considerations and validity 
The strength and limitations in terms of the study design and questionnaire are at large similar 
to what’s described for Study I. In contrast to Study I, all data was collected through written 
questionnaires instead of interviews. This resulted in more missing data but even after 
excluding questionnaires with too much missing data, the participation rate was still at high 
85%. On the other hand, the use of questionnaires might reduce reporting bias and social 
desirability bias. The women might have perceived that acceptance was the socially preferred 
answer, and might have felt pressured to answer “correctly”, and this source of error could 
have been lower for the written questionnaire technique. This might also be the case for 
potential bias related to questions regarding sensitive matters such as income or daughters 
sexual history. Acceptance was slightly lower in this study compared to Study I, yet the use 
of questionnaire or interview-based technique have probably not influenced these results in 
any major way.  
 
Another important aspect was that there was an uneven distribution of study participants, 
with 86% from the public and the 14% from the private sector. However, we believe that this 
may be fairly representative, as women of low socioeconomic status constitute a large part of 
the Argentinean population. 
 
A major limitation of this study was that the regression analysis was limited to investigate 
only correlates of willingness to pay for HPV vaccination, compared to willingness if 
vaccination was free. It would have been interesting to investigate correlates of vaccination 
for free compared to those who were unsure or unwilling to vaccinate their daughter, 
especially since vaccination is free of charge in the school-based vaccination program. 
However, due to few numbers, we were not able to perform this analysis.   
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6.3 STUDY III 
6.3.1 Main findings and interpretations 
This study found that the estimated mean total time and travel costs and direct non-medical 
cost for women attending cervical cancer screening in Sweden was substantial and might be 
an obstacle to screening and may affect the overall cost-effectiveness.  
 
Another important finding was that nearly half the women did not attend screening within 
one year from their invitation, of which half cited difficulties in taking time off work. Also, 
there was a statistically negative association between screening compliance and need to take 
time off work, and screening compliance decreased with increasing number of hours needed 
off work. This suggests that difficulties in taking time off work could constitute a barrier to 
screening. Increased flexibility by extended opening hours is one possibility to target this 
issue.  
 
Also having a companion to screening correlated negatively with screening participation. In 
our study, one in ten women brought a companion and it is important to understand the 
reason for this. Among women who did not attend screening within one year from their 
invitation, 16% expressed other reasons, including fear of gynecological examination and 
previous negative experiences. The choice of having a companion might be due to such 
reasons. This is something that should be further investigated.  
 
Another finding of importance was that women with higher HPV knowledge had higher 
screening compliance. HPV knowledge, in turn, was higher among younger women and 
women with higher level of education. Still, overall knowledge of HPV was quite low. Less 
than half knew that HPV is transmitted sexually, that it can infect both men and women and 
that it could cause dysplasia. Also, one third of the women did not know the purpose of 
screening, but believed it to protect from all gynecological cancer. Over 60% were however 
aware of the existence of HPV vaccines. Education is thus needed and may be used to 
improve screening participation.  
 
6.3.2 Comparisons with other studies 
The importance of costs as a barrier to screening was shown when a fee was introduced for 
cervical cancer attendance in Stockholm. The participation rate fell by 23% but rose again 
after removal of the fee (107). Also in a study that investigated participation in 
mammography screening among low-income women, a higher participation rate was 
observed in women who were assigned a voucher for a free mammogram compared to those 
who had to pay the fee. The main reason for non-participation among women without a 
voucher was costs, while it was transportation for those with a voucher (112). In most 
counties in Sweden, there has been a fee for cervical screening (189), which could have been 
an obstacle for cervical cancer attendance. As of January 2018, cervical cancer screening is 
free-of-charge throughout the country (190), which is important for reducing cost-related 
barriers to screening.  
 
Previous studies from Sweden have reported that screening participation is lower among 
younger women, women who are single, immigrant women and women who are outside the 
labor force (108, 109). A large recent population-based case-control study on 600,000 
Swedish women, showed a strong association between socioeconomic status and screening 
participation. Important factors associated with lower screening participation were low 
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disposable family income, low education and not cohabiting (110). This suggests that there 
are socioeconomic inequalities in access to screening which need to be targeted.  
 
A meta-analysis on qualitative research addressed how women’s experiences and perceptions 
influenced screening uptake. Two major themes were identified: questioning the relevance 
and the value of participation and screening posing a threat or previous negative experiences 
(111). Some of the women in our study also expressed the latter reason, which is something 
to address further. 
 
6.3.3 Methodological considerations and validity 
The strength of this study is that it provides important estimates of on non-medical direct and 
indirect costs related to cervical cancer screening. This is something that has not always 
been accounted for in previous economic analyses. These findings can be used in future 
cost-effectiveness evaluations. Also, this study offers important insights on associations of 
HPV knowledge and screening compliance. A methodological strength is our high-quality 
data, as the non-participation rate was negligible, and there was neither any missing data. 
The questionnaire used in this study was neither formally validated; however, the cost 
section was based on recommendations from a working group on how to inquire patient-
reported costs and the knowledge questions based on previously used questionnaires for 
this area, as described in detail in the methods section. Also, the Cronbach’s alpha 
coefficient showed acceptable results regarding internal reliability. The questionnaire was 
also piloted prior to the study without any findings of misunderstandings or 
misclassifications.  
 
The limitations of this study include that the study was performed in a county without fee 
for cervical cancer screening, which restricted us from examining its potential influence on 
screening compliance. On the other hand, this fee has now been removed throughout the 
country (190), as stated above, and is not as important today. Also, our cost estimates for 
women living in this capital region, might not be transferable to other settings in Sweden 
with longer geographical distances to screening clinics and less possibility to use 
transportation by walking or cycling (i.e. modes without any additional costs). In our 
material, almost 40% of women used transportations without costs. Additionally, longer 
distances results in increased travel costs but also longer time off work, and higher costs 
due to production loss related to this. On the other hand, women who had a companion to 
screening and those in need of child care in order to attend screening incurred higher costs. 
It is unclear if there are differences throughout the country with respect to these issues. 
 
Another important limitation is that this study only included women attending cervical 
cancer screening and we do not have information on correlates of screening compliance for 
women who never attend screening. Further, when we compared our study women to the 
general population, there was a significant underrepresentation of women of low 
socioeconomic status, suggesting a possible selection bias. On the other hand, we know 
from the studies stated above that women of low socioeconomic status are underrepresented 
in screening (110), and our study population might be fairly representative. Our findings 
that cost and having difficulties in taking time off work could be barriers to screening could 
still be applicable to other socioeconomic groups as well.  
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6.4 STUDY IV 
6.4.1 Main findings and interpretations 
This study found that one third of the cone biopsies was incomplete at one or more margins, 
or of uncertain margin status. Median follow-up time was 10 years and almost nine out of ten 
women were followed 6 to 16 years. We found that 12% of the women developed residual or 
recurrent high-grade dysplasia or worse during follow-up and there were a higher proportion 
of involved margins in the recurrence group compared to the non-recurrence group. 
  
Our study showed that women with involved margins had statistically significantly worse 
outcomes compared to women with negative margins even after adjustment for comorbidity, 
age at surgery, the severity of the lesion, treatment modality and previous conization 
procedures. The risk for residual or recurrent CIN2+ was almost 3-fold higher among women 
with involved endocervical margins, involved margins and uncertain if endocervical or 
vaginal, and especially when both margins were involved compared to women with negative 
margins. Also, women with history of previous conization procedure and comorbidities were 
at higher risk of recurrent CIN2+.  
 
Few women were HPV-tested at any time during follow up, which was expected as the 
women in our study were treated before the introduction of HR-HPV test as a follow-up test-
of-cure. In women with an HPV test taken, margin status remained statistically significantly 
associated with increased risk of recurrent or residual disease. Also in women who were 
positive for HR-HPV during follow-up, there was a tendency of an increased risk for 
recurrent CIN2+ among women with involved margins, although it did not reach formal 
statistical significance, probably due to power limitations. 
 
6.4.2 Comparisons with other studies 
Residual or recurrent disease was detected in 12% of women, in our study which was higher 
than overall findings of 7 to 9% in two meta-analyses (97, 98), even though the first analysis 
also included any grade of post-treatment disease (98). The higher proportion in our study 
might be explained by our long follow-up time, enabling us to detect late recurrence. One of 
the meta-analyses included studies with a lower limit of 18 months mean follow-up (97), and 
the other had no lower limit (the shortest with 3 months follow-up) (98). Another causal 
factor to the high recurrence rate in our study could be that 31% of the margins were 
involved, which was higher than the 23% observed in the meta-analyses (range 3-60) (97, 
98). According to the European Federation of Colposcopy (EFC), a complete excision rate 
of above 80% is considered to be an important quality indicator (217). Both meta-analyses 
showed a 4-6 fold higher risk of recurrent CIN2+ in women with involved margins compared 
to negative margins (97, 98), corroborating our findings on a positive association between 
incomplete excision and recurrence.  
 
It has been shown that HR-HPV test is more accurate to use during follow-up than margin 
status, with higher sensitivity (91% vs. 56%) and equal specificity (both 84%) to detect 
recurrent high-grade disease (97). The Swedish national cervical cancer guidelines from 2017 
recommend co-testing (cytology + HPV-DNA test) as a test-of-cure during follow-up. It is 
advised against re-treatment on the basis of positive margins alone (47). We strongly agree 
with this. Data from meta-analyses have shown only one out of five women with involved 
margins develop residual or recurrent disease (97, 98). However, we found consistently 
worse outcomes in women with involved endocervical margins, in women where it was 
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uncertain whether or not the endocervical margin was involved, and especially in women 
where both margins were involved compared to those with negative margins. Similar findings 
have been reported in other studies (218). Also, the recent meta-analysis confirmed women 
with involved endocervical margins to be a high-risk group for recurrent disease compared to 
women with negative margins (97).  
 
It could be that women with involved endocervical margins or involvement of both margins, 
who are HR-HPV persistent during follow-up, should be handled more rapidly. This would 
be particularly important if the woman is infected with one of the more potent HR-HPV types 
(HPV 16/18) (55). The use of non-stratified margin status in combination with follow-up HR-
HPV has not been shown to be superior in the meta-analysis (97). However, we did not find 
any association with residual/recurrent disease when the vaginal margin was involved alone. 
Nor did the meta-analyses (97, 218). In contrast, a study that only combined endocervical 
margin status with follow-up HPV test reported a positive predictive value of 94% and 
negative predictive value of 96% to predict residual or recurrent disease (219). Such 
combination should thus be further investigated. 
 
6.4.3 Methodological considerations and validity 
A major strength of this study was the long follow-up time, to be able to evaluate the impact 
of margin status and risk of residual or recurrent disease over time. Another important 
strength was the complete coverage of the Swedish National Cervical Screening Registry, 
providing reliable data on recurrent high-grade dysplasia on all included women, as 
previously described in the methods section. However, the registry provides only limited data 
on recurrence outside the cervix (VAIN, vaginal cancer, or recurrence to the pelvis or other 
location), which still could be a recurrent CIN. Hence, this was included as a residual or 
recurrent disease case when data on such was found in the medical record but the true 
recurrence rate could still be slightly higher. Still, this should not have influenced our 
findings in any major way. Neither do we have information on re-treatments or subsequent 
hysterectomies that occurred outside Karolinska Hospital.  
 
A major limitation was that we only had information on HPV status on one out of five 
women, of which less than 10% were HR-HPV positive at any time during follow-up. It 
could be that the women who were HPV-tested had a higher baseline risk for recurrent 
disease than women who were not tested. Also, women who were diagnosed and treated for 
residual/recurrent disease could have a longer follow-up time with an increased chance of 
HPV test being taken. Due to the risk of introducing bias when adjusting for this variable, we 
decided not to include it in the Cox regression analysis. On the other hand, we performed a 
separate Cox regression in which we stratified for HPV status to further evaluate the potential 
of HPV as a potential confounder. It was however found that the association with involved 
margins remained and almost reached statistical significance also for HR-HPV positive 
women, despite the rather small sample size. This may speak against confounding by HPV on 
our findings of a positive association between margin status and recurrent disease.  
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7 CONCLUSIONS 
7.1 STUDY I 
This study found a very high HPV vaccination acceptance among young Argentinean women 
from a non-metropolitan region, and acceptance was also high when vaccination was not free 
of charge. The latter is especially important, since there is no subsidized catch-up vaccination 
for this age group in Argentina. This holds great potential for disease prevention among 
Argentinean women at high risk of cervical cancer. However, women who received welfare 
were less willing to pay for vaccination, which suggests that cost could be a barrier and may 
lead to socioeconomic inequalities in uptake. Also, women who did not perceive vaccination 
as safe in general were less willing to accept vaccination. Educational campaigns ensuring the 
safety of vaccines, as well as clarifying other misconceptions are needed.  
 
7.2 STUDY II 
In conclusion, this study has shown a high HPV vaccination acceptance for daughters among 
mothers from a non-metropolitan part of Argentina. This is of major importance for a country 
with insufficient cervical cancer screening coverage and a high burden of cervical cancer. It 
was also shown that acceptance of vaccination decreased when out of pocket payment was 
needed. Further, being gainfully employed and having a higher disposable household income 
was significantly associated with acceptance of vaccination if it was not free. Taken together, 
these results suggest that cost could be an obstacle to catch-up vaccination. Also, women with 
prior awareness of cervical cancer were more willing to pay for HPV vaccination, indicating 
the importance of improving awareness of HPV and its related diseases. 
 
7.3 STUDY III 
The results of this investigation show that the estimated total time and travel costs and direct 
non-medical cost for women attending cervical cancer screening in Sweden was substantial 
and might be an obstacle to screening and may affect the overall cost-effectiveness. It was 
also found that nearly half of the women did not attend screening within one year from their 
invitation, of which half cited difficulties in taking time off work. The most important 
correlates of higher screening compliance were not needing to take time off work, not having 
a companion and being of higher HPV knowledge. Increased flexibility by extended opening 
hours and improved general knowledge of HPV may facilitate screening compliance.  
 
7.4 STUDY IV 
This research has shown that 12% of the women treated for precancerous lesions were 
diagnosed with residual or recurrent disease after a median of 10 years follow-up. Cox 
regression analyses revealed that women with involved margins had significantly worse long-
term outcomes compared to women with negative margins. The risk was almost 3-fold higher 
among women with involved endocervical margins, involved margins and uncertain as to 
whether these were endocervical or ectocervical, and especially when both margins were 
involved. These findings suggest that stratified margin status may contribute to the safety of 
the follow-up surveillance. 
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8 FUTURE DIRECTIVES 
There is still very little research on HPV vaccination acceptance from Argentina, both 
regarding parental vaccination acceptance and acceptance among adults. To the best of my 
knowledge, only one additional study has been published on this topic since our research was 
conducted. There is a continued lack of large-scale nationwide studies. Also, information on 
the actual uptake of HPV vaccination from Argentina is limited and of uncertain quality. It is 
of great importance to achieve high HPV vaccination uptake in a country like Argentina, with 
high cervical cancer burden and suboptimal screening. However, it has been reported that 
full-dose vaccination coverage was only 50% in the 2000 birth cohort (118), and even lower 
local figures have been presented, with as 2-dose uptake of only 25% in the Chaco province 
based on data from 2012 (215). If national coverage is as low as these figures suggest, it is 
vital to understand why and to target these issues. Further research should explore this. 
Findings from our studies suggest that educational campaigns ensuring the safety of vaccines, 
as well as clarifying other misconceptions are needed. However, this might be more complex 
than it seems. There was a mass media campaign in connection with the introduction of the 
HPV vaccines in Argentina but it was stopped due to criticism (185). Therefore, strategies for 
developing and implementing educational campaigns for this particular setting are needed. 
Our findings also suggest that cost could likely pose a barrier to catch-up vaccination, as this 
is to be self-financed in Argentina. Thus, this can lead to socioeconomic inequalities in 
uptake among the catch-up population and may increase the already existing inequalities in 
cervical cancer burden throughout the country. This is something that decision makers should 
address. On a more promising note, Argentina has recently introduced HPV based screening 
(220). It will be very interesting to follow this process and to see if it can improve the 
country’s screening.  
 
Also, our finding that cost can be a barrier to participation in cervical cancer screening in 
Sweden is important to continue to explore. A large recent Swedish study has shown that 
women of low socioeconomic status are underrepresented in screening (110). It is thus 
important that the screening organization facilitates the participation of all women in Sweden, 
including all socioeconomic groups. Unskilled workers may have less possibility to take time 
off work compared to non-manual workers. One possibility to address this could be through 
increased opening hours in order to facilitate attendance, irrespective of the type of work. 
Future research should address this. Also, it is important to explore reasons for bringing a 
companion to screening, and to investigate if these women also are the same as those who 
describe previous negative experiences of screening. A promising field is the use of HPV 
self-sampling for non-attendees of screening in order to improve screening uptake. It will be 
of great interest to follow the research development in this area and to see if it can be used 
among non-attendees also on a nationwide basis.  
 
Last but not least, our findings showed promising results on the use of sub-stratified margin 
status to assess the risk of recurrent disease among women previously treated for cervical 
cancer. The possibility of using sub-divided margin in combination with HR-HPV to identify 
individuals in need of re-treatment should be addressed. The clinical implication and the 
accuracy of such combination strategies should be further investigated. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Livmoderhalscancer är en sjukdom som till stor del går att förebygga med screening och 
förebyggande vaccination mot humant papillomvirus (HPV). Trots det är det globalt sett den 
fjärde vanligaste cancerformen hos kvinnor och drabbar årligen en halv miljon kvinnor, med 
en kvarts miljon relaterade dödsfall. Till skillnad från andra cancerformer inträffar ungefär 
hälften av alla nya fall bland kvinnor yngre än 50 år. Förekomsten av livmoderhalscancer 
uppvisar stora geografiska skillnader, och ungefär 85 % av nya fall och dödsfall sker i 
låginkomstländer. Det finns två huvudsakliga typer av livmoderhalscancer; skivepitelcancer 
och adenocarcinom. Dessa utgår från två av de celltyper som finns i livmodertappen, och den 
vanligaste är skivepitelcancern som utgör strax över 80 % av alla fall. Livmoderhalscancer 
orsakas av HPV som är den vanligaste sexuellt överförbara infektionen globalt. HPV kan 
även orsaka cancer som drabbar munhåla, halsmandlar, ändtarmsöppningen, slida, vulva och 
penis. Det finns 13 stycken så kallade hög-risk HPV-typer som kan orsaka 
livmoderhalscancer: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 och 68. Av dessa är 
HPV 16 och 18 de vanligaste och orsakar ungefär 70 % av all livmoderhalscancer. Det är 
dessa två typer som ingår i de två vacciner som används i de nationella 
vaccinationsprogrammen runt om i världen (Cervarix
®
 och Gardasil
®
).  Sedan 2014 finns 
det ytterligare ett HPV-vaccin som täcker totalt nio HPV-typer (6, 11, 16, 18, 31, 33, 45, 52, 
och 58, Gardasil 9
®
). Detta vaccin skyddar mot ungefär 90 % av all livmoderhalscancer och 
finns nu även tillgängligt i Sverige. Hos de flesta läker HPV-infektionen ut spontant, men i 
ungefär 10 % kvarstår infektionen, och kan över tid utvecklas till livmoderhalscancer. 
Screening för livmoderhalscancer syftar till att upptäcka förstadier till livmoderhalscancer, så 
kallade cellförändringar, och behandla dessa innan cancer utvecklas. Alla cellförändringar 
utvecklas inte till cancer utan kan gå tillbaka spontant, men möjligheten till utläkning minskar 
med ökande grad av cellförändringar. Screeningen har funnits i Sverige sedan 1960-talet och 
har minskat förekomsten av livmoderhalscancer med ungefär två tredjedelar. Den nedgång 
man förut såg i incidensen av livmoderhalscancer i Sverige har stagnerat de senaste åren, och 
cancerformen ökar för närvarande igen. Kvinnor som inte deltar i screeningen och kvinnor 
som tidigare har haft cellförändringar har visat sig ha en ökad risk för livmoderhalscancer. I 
Argentina är livmoderhalscancer fortfarande den andra vanligaste cancerformen hos kvinnor 
och dödligheten har legat oförändrad de senaste 30 åren. Landet har så kallad opportunistisk 
screening, vilket innebär att kvinnor inte kallas regelbundet till screening såsom i Sverige, 
utan istället tas cellprov om kvinnor söker gynekolog av annan anledning. Detta är inte en 
effektiv metod, vilket är en stor bidragande faktor till att sjukdomsbördan fortfarande är hög i 
landet. Sedan 2011 har Argentina gratis vaccination mot livmoderhalscancer för 11-åriga 
flickor. HPV-vaccination förutspås ha allra störst inverkan i länder som Argentina, med en 
hög förekomst av livmoderhalscancer och en inte fullt så välfungerande screening.  
 
Det övergripande syftet med denna avhandling är att bidra till att förbättra förebyggandet av 
livmoderhalscancer, både i länder med hög och låg sjukdomsbörda. Den relativa betydelsen 
av de olika förebyggande metoderna skiljer sig åt i olika delar av världen. Därför var avsikten 
att studera viljan at vaccinera sig mot HPV i Argentina, att identifiera vad som utgör barriärer 
och möjliggöra ett effektivare screeningdeltagande i Sverige, samt att undersöka 
långtidsrisken att återinsjukna med cellförändringar hos kvinnor som tidigare genomgått 
behandling för cellförändringar i Sverige utifrån om det fanns cellförändringar i 
operationsmaterialets resektionsrand.  
 
I både den första och andra delstudien undersökte vi vad som påverkade viljan att vaccinera 
sig mot HPV hos kvinnor i Mendoza-provinsen i Argentina. I den första studien undersöktes 
viljan att vaccinera sig mot HPV hos 174 stycken unga kvinnor i åldrarna 18-30 år med hjälp 
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av ett strukturerat intervjuformulär. Nästan alla kvinnorna sa sig vara villiga att vaccinera sig 
mot HPV och tre fjärdedelar sa sig vara villiga att betala för vaccinationen. Kvinnor med 
generell tilltro till vaccin var mer villiga att vaccinera sig mot HPV, och kvinnor som inte fick 
socialbidrag var mer villiga att betala för vaccination. I den andra studien undersöktes viljan 
att låta vaccinera sina döttrar, hos 180 mödrar till flickor i åldrarna 9-15 år genom 
frågeformulär.  Nio av tio mödrar var villiga att vaccinera sina döttrar om vaccination var 
gratis och 60 % sa sig även vara villiga att betala för vaccination. Kvinnor som hade hört 
talas om livmoderhalscancer innan studien var mer villiga att betala för HPV-vaccination, 
vilket betonar vikten av att öka medvetenheten om sjukdomen i samhället. Förvärvsarbetande 
mödrar samt kvinnor med högre disponibel hushållsinkomst var mer villiga att betala för 
vaccination. Detta, tillsammans med fynden i den första delstudien pekar på att höga 
vaccinkostnader kan utgöra ett hinder för HPV-vaccination av flickor som är äldre än 11 år 
och inte omfattas av vaccinationsprogrammet. Dessa individer behöver själva stå för 
kostnaderna, vilket kan leda till social orättvisa gällande tillgång till vaccination. Ytterligare 
fann studierna ett behov av att bemöta och förtydliga HPV-vaccinets säkerhet. 
 
I den tredje delstudien efterforskade vi eventuella hinder till screeningdeltagande i Sverige. 
Totalt 1510 kvinnor som deltog vid den organiserade cellprovtagningen i Stockholm svarade 
på ett frågeformulär gällande resekostnader och andra kostnader för att delta vid screeningen, 
samt kunskap om livmoderhalscancer och HPV. Vi fann att genomsnittskostnaden för 
produktionsbortfall, reskostnader och andra utlägg för kvinnan var hög (EUR 55.6), och 
skulle kunna påverka deltagande i screeningen samt screeningprogrammets 
kostnadseffektivitet. Vidare fann vi att nästan hälften av alla kvinnor inte hade gått på 
screeningen inom ett år från sin kallelse, varav hälften angav svårighet att ta ledigt från 
arbetet. De viktigaste faktorerna som påverkade screeningdeltagandet var att inte behöva ta 
ledigt från arbetet, att inte ha en anhörig eller annan medföljande till besöket, och att ha högre 
kunskap om HPV. Kunskapen om HPV var generellt låg, men något bättre bland yngre. Ökad 
kunskap om HPV skulle kunna öka screeningdeltagandet. Eftersom kvinnor med sämre 
deltagande i screeningen till stor del uppgav svårigheter att ta ledigt från arbetet kan ett sätt 
att öka följsamheten vara att förändra öppettiderna till att inkludera kvällar och helger. Utöver 
detta skulle kostnader kunna utgöra ett hinder för deltagande. Därför är det viktigt att den 
organiserade screeningen möjliggör deltagande för alla kvinnor i Sverige, oavsett 
socioekonomisk grupp. Den nyligen borttagna avgiften för cellprovtagning i hela Sverige är 
ett mycket bra och välkommet exempel på detta.  
 
I den fjärde och sista delstudien undersöktes långtidsrisken för återkomst av cellförändringar 
hos kvinnor som tidigare genomgått kirurgisk behandling av höggradiga cellförändringar (så 
kallad konisering), utifrån om det fanns cellförändringar i operationsmaterialets 
resektionsrand. Nästan 1000 kvinnor som behandlats på Karolinska Universitetssjukhuset i 
Stockholm under åren 2000-2007 följdes upp med hjälp av data från det Nationella 
Kvalitetsregisteret för Cervixcancerprevention. Under uppföljningstiden på upp till 16 år 
diagnosticerades 12 % av kvinnorna med kvarvarande eller återkomna höggradiga 
cellförändringar. Kvinnor som hade cellförändringar i resektionsranden hade en ökad risk för 
återkomst av sjukdom jämfört med kvinnor med fri resektionsrand. Risken var trefaldigt ökad 
om cellförändringarna fanns i resektionsranden mot livmodern, om det var oklart huruvida 
cellförändringarna fanns i resektionsranden mot livmodern eller mot slidan, och i synnerhet 
om cellförändringarna fanns i bägge resektionsränderna. Däremot fann vi ingen ökad risk om 
cellförändringarna bara fanns i resektionsranden mot slidan. Dessa fynd indikerar att 
riskbedömningen av patienter efter behandling skulle kunna förbättras om hänsyn togs till de 
kvarvarande cellförändringarnas lokalisation. Framtida studier bör undersöka möjligheten att 
kombinera fynden från resektionsranden med nuvarande praxis.  
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Sammanfattningsvis har denna avhandling bidraget med information om vad som kan utgöra 
hinder för HPV-vaccination och deltagande i screening mot livmoderhalscancer och gett 
förslag på möjliga förbättringsområden för att öka täckningsgraden. Att bemöta och 
förtydliga HPV-vaccinets säkerhet och att öka kunskapen om HPV i befolkningen skulle 
kunna vara viktiga åtgärder. Våra fynd indikerar att kostnad kan vara ett hinder både för 
vaccinationstäckning i Argentina samt vid deltagande vid screening i Sverige, vilket vårdens 
beslutsfattare bör ta i beaktande. Slutligen har denna avhandling visat att kvinnor med 
kvarvarande cellförändringar i resektionsranden efter kirurgisk behandling har en ökad risk 
för återkomst av cellförändringar, och att olika risker kunde ses beroende på var de 
kvarvarande cellförändringarna fanns. Framtida forskning bör se över möjligheten till att 
kombinera fynden från resektionsranden med gällande uppföljningsstrategier. Dessutom finns 
ett stort behov av uppföljning efter införandet av HPV-vaccination i Argentina.   
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